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 The overall goal of this thesis project was to investigate the role of mitochondria 
(MT) in the very early pathogenesis of posttraumatic osteoarthritis (PTOA) and to test 
mitoprotection as a strategy to prevent chondrocyte death and cartilage degeneration after 
cartilage injury.  
 Ankle sprain is the most common athletic injury, and the most common cause of 
end-stage ankle osteoarthritis (OA). Evidence suggests that the magnitude of the initial 
cartilage/subchondral bone injury is the most important factor in the development of 
sprain-associated PTOA. However, most PTOA models utilize the knee and rely on joint 
destabilization or intraarticular fracture to initiate disease. These models cause rapid 
progression of cartilage pathology with severe synovitis and do not reflect the likely 
etiology of ankle PTOA resulting from a high-speed impact injury. Therefore, the first 
aim of this dissertation research was to develop a clinically relevant large animal model 
of impact-induced talocrural (ankle) PTOA. A minimally invasive surgical approach was 
used to apply rapid impact injuries to the equine talus. Twelve weeks after injury, the 
severity of cartilage lesions was positively correlated to peak impact stress. The 
significance of this work is that it allows us to directly link in vitro mechanistic studies to 
in vivo longitudinal studies of disease development, using the same impact system. This 
model will also allow preclinical testing of disease modifying OA drugs.   
 The second aim of this thesis was to study MT function of chondrocytes within 
their native extracellular matrix immediately following a single, rapid impact, which 
simulates an injury expected to initiate PTOA in vivo. Fresh cartilage explants were 
subjected to injury at varying stress rates. MT respiratory rate and control were assessed 
by microrespirometry. Functional integrity of the inner MT membrane was investigated 
using polarity-sensitive fluorescent probes on confocal microscopy. We found that injury 
resulted in decreased basal and maximal chondrocyte respiration as well as MT 
depolarization within hours of cartilage impact, indicating that MT dysfunction is an 
acute response of articular cartilage to injury. The response of chondrocytes differed 
between two areas of the same joint; chondrocytes from a non-weight bearing articular 
surface (the distal patellofemoral groove) were more sensitive to MT dysfunction and 
chondrocyte death than the main weight-bearing surface of the knee (the medial femoral 
condyle), indicating regional differences in mechanotransduction. These findings suggest 
that MT may represent an early therapeutic target in the prevention of PTOA.  
 The third aim of this thesis work was therefore to investigate mitoprotection as a 
strategy to prevent chondrocyte death and cartilage degeneration in vitro. SS-31 is a 
highly targeted peptide antioxidant that prevents MT respiratory dysfunction, MT-
mediated apoptosis, and ROS production by stabilizing the MT-specific phospholipid 
cardiolipin. Cartilage was injured, then treated with SS-31 at 0, 1, or 6 hours after injury, 
and cultured for 1 week. We found that SS-31 prevented impact induced chondrocyte 
death, apoptosis, and cartilage matrix degradation at 1 day and 1 week after injury. Our 
findings indicate that mitoprotective therapy within 6 hours after joint injury may be a 
useful strategy to prevent PTOA.   
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CHAPTER 1 
 
GENERAL INTRODUCTION 
 
Goals of the dissertation research and thesis overview 
  The overall goal of this thesis project was to investigate the role of mitochondria 
(MT) in the early pathogenesis of posttraumatic osteoarthritis (PTOA). This introductory 
chapter provides relevant background related to cartilage pathobiology, clinical PTOA, 
MT function in health and disease, and rationale to support the clinical concept of 
targeted MT therapy (i.e. mitoprotection) to prevent osteoarthritis.  
 The first aim of this dissertation research was to develop a clinically relevant 
large animal model of talocrural (ankle) PTOA. Chapter 2 presents the rationale for this 
aim in detail, Chapter 3 describes ex vivo model development and in vivo validation 
studies. The significance of this work is that it allows us to directly link in vitro 
mechanistic studies to in vivo longitudinal studies of disease development, using the same 
impact system.  
 The second aim of this thesis, presented in Chapter 4, was to determine the effects 
of cartilage impact injury on chondrocyte MT function in situ. Specifically, the goal was 
to study MT function of chondrocytes within their native extracellular matrix 
immediately following a single, rapid impact, which simulates an injury expected to 
initiate PTOA in vivo. We found that MT respiratory function declined, and MT 
depolarization occurred within hours of cartilage impact, indicating that MT dysfunction 
is an acute response of articular cartilage to mechanical injury. The response of 
chondrocytes differed between two areas of the same joint; chondrocytes from a non-
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weight bearing articular surface (the distal patellofemoral groove) were more sensitive to 
MT dysfunction and chondrocyte death than the main weight-bearing surface of the knee 
(the medial femoral condyle), indicating regional differences in mechanotransduction. 
These findings suggest that MT may represent an early therapeutic target in the 
prevention of PTOA.  
 The third aim, presented in chapter 5, was to investigate mitoprotection as a 
strategy to prevent early PTOA changes in vitro. SS-31, a highly targeted mitoprotective 
drug, provided cellular and structural protection 1 day and 1 week after cartilage injury. 
Treatment with SS-31 at 0, 1, or 6 hours after injury prevented impact-induced cell 
membrane damage, chondrocyte death, apoptosis, and cartilage extracellular matrix 
degeneration. Our findings indicate that mitoprotective therapy within 6 hours after joint 
injury may be a useful strategy to prevent PTOA.   
 The final chapter of this thesis presents a discussion of the significance of our 
findings in the context of the current state of PTOA research and therapy. Future research 
directions are explored.        
 
Background and significance 
Osteoarthritis 
 Osteoarthritis (OA) is the leading cause of chronic disability in the United 
States.1,2 The estimated total annual cost exceeded $160 billion in 2014.1,3 OA can 
generally be described as degenerative disease of articular cartilage, however all joint 
tissues are affected including subchondral bone, synovium, and joint capsule. In most 
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clinical cases, the etiopathogenesis of OA is multifactorial, with age, weight, disease, and 
genetics all likely playing a role.   
  
Posttraumatic osteoarthritis 
 In addition to biological factors, OA is a disease of mechanics.2,4-6 Post-traumatic 
osteoarthritis (PTOA) develops secondary to joint trauma with clinical signs of pain and 
dysfunction often lagging years or decades behind the initiating injury.7,8 Currently, no 
effective therapy exists to prevent or slow progression of PTOA,9 and mounting evidence 
suggests that interventions must occur in the acute time frame after injury to modify the 
disease course.6 Therefore, understanding the immediate events following joint impact 
injury is critical for developing effective preventative therapies.10 Some of the earliest 
known pathomechanisms of OA, such as oxidative stress and chondrocyte apoptosis, are 
regulated by mitochondria.11,12  
 
Mitochondria  
 Mitochondria (MT) sustain eukaryotic cellular life and dictate cell fate. The 
natural history of this semi-autonomous organelle might explain many peculiar features 
of MT, including their double membrane structure, distinct genome of circular DNA 
(mtDNA), autonomous replication and translation machinery, and strict maternal mode of 
inheritance.13 MT evolved from rickettsia-like, endosymbiotic bacteria roughly 1.5 billion 
years ago.14 Over 150 human diseases arise from point-mutations affecting one of the 
roughly 1,100 proteins comprising the MT proteome.13 
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Mitochondrial function and structure 
 The most important functions of MT within the context of this thesis are: 1) 
energy production, 2) production and neutralization of reactive oxygen species (ROS), 3) 
regulation of apoptosis, and 4) calcium buffering.  
 Energy Production. MT produce ATP by oxidative phosphorylation, providing 
the energy required for cells to survive, maintain cell membranes and electrochemical 
gradients, reproduce, and perform tissue-specific biological functions such as synthesize 
and export proteins, maintain the extracellular matrix, etc. Oxidative phosphorylation is 
carried out by the electron transport chain, a series of protein complexes that reside 
within the inner MT membrane (Figure 1.1). The high-energy molecules NAD and 
FADH2 derived from non-MT respiration (glycolysis) and the Krebs cycle, donate 
electrons to complexes I and III of the electron transport chain. Through a series of 
oxidation-reduction (redox) reactions, electrons are passed along the electron transport 
chain, causing protons to be pumped across the inner MT membrane into the 
intermembrane space. This creates potential energy in the form of an electrochemical 
gradient. Oxygen (O2) acts as the final electron acceptor, and is converted to H2O and H+. 
Protons flow down their gradient through the enzyme ATP synthase, causing the A0 
subunit to rotate and phosphorylate ADP to generate ATP.    
 ROS production and neutralization. ROS is a term used to describe molecules and 
free radicals, including superoxide (O2-), nitric oxide (NO) and hydrogen peroxide 
(H202), which are derived from oxygen. The main intracellular source of ROS is the MT,  !!
! 5 
 
 
 
Figure 1.1.  Mitochondrial respiration. Nutrients such as glucose enter the cell and are 
metabolized through anaerobic, non-mitochondrial respiration (glycolysis) in the cytosol. In the 
presence of oxygen (O2), pyruvate enters the Krebs cycle in MT to produce NADH and FADH2, 
which donate electrons (e-) to the electron transport chain (ETC.) The transfer of e- between 
complexes I-IV drive protons across the inner MT membrane (IMM), establishing an 
electrochemical gradient. Cytochrome C (Cyt C) catalyzes the rate-limiting step and O2 acts as 
the final electron acceptor. When protons flow down their gradient through ATP synthase, ADP 
is converted to ATP, the molecular unit of cellular energy. This process of MT respiration or 
oxidative phosphorylation (OxPhos) generates reactive oxygen species (ROS) as a byproduct.     
 
 
 
! 6 
where they are produced as a byproduct of oxidative phosphorylation.15 Approximately 
0.2-2% of O2 consumed by oxidative phosphorylation is converted to superoxide in the 
electron transport chain, mainly by complexes I and III.16 ROS play diverse roles in cell 
signaling and homeostasis.17-19 For example, in cartilage, ROS are critical in ion 
homeostasis and cartilage differentiation.16 However, by virtue of their unstable bonding 
structure, which often includes an unpaired electron, they can act as potent oxidizing 
agents, resulting in damage to lipid membranes and DNA. Therefore, redox balance is 
tightly regulated by multiple antioxidant systems, the most notable of which is the 
superoxide dismutase (SOD) family of antioxidants. Members of the SOD family convert 
superoxide to H202, and occur in the cytoplasm (SOD1), within MT (SOD2, aka MnSOD) 
and extracellularly (SOD3).  
 Calcium buffering.  Calcium signaling governs many basic cell functions. 
Intracellular calcium concentrations are primarily controlled by flux across the plasma 
membrane,20 while transient cytosolic Ca+2 concentration is determined by Ca+2 
distribution between three intracellular compartments; the cytosol, the endoplasmic 
reticulum, and the MT.21  MT contribute to intracellular Ca+2 homeostasis during 
episodes of cellular stress and intracellular hypercalcemia. MT can rapidly take up 
cytoplasmic Ca+2  into the matrix through the calcium uniporter on the inner MT 
membrane, increasing MT Ca+2 up to 1,000-fold, transiently store it, then release it back 
into the cytosol.22 During MT dysfunction, increased intra-MT Ca+2 is pro-apoptotic by 
contributing to opening of the MT transition pore.23  
 Apoptosis.  The basic pathway of MT-mediated controlled cell death by apoptosis 
is initiated when cytochrome C (CytC) dissociates from the inner MT membrane, and 
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members of the Bcl-2 family of proteins cause permeabilization of the outer MT 
membrane, allowing Cyt C and other MT proteins to leak into the cytosol (Figure 1.2). 
CytC initiates oligomerization of APAF-1, recruitment and dimerization of caspase-9 and 
formation of the apoptosome. Caspase-9 is activated, which in turn cleaves caspase-3 and 
-7. Activation of these ‘executioner’ caspases commits the cell to death by apoptosis.24  
 Cardiolipin.  Cardiolipin (CL) is a phospholipid exclusively expressed on the 
inner MT membrane, and comprises ~10% of its content.25 CL is a dimer, with small 
acidic head groups and four diverging hydrophobic acyl chain tails, resulting in a conical 
shape. This shape promotes curvature of the inner MT membrane and formation of cristae 
structure (Figure 1.2). CL rafts allow electron transport chain proteins to form 
supercomplexes, which optimizes the efficiency of electron transport chain, increasing 
ATP production and reducing ROS generation.26 
 Cytochrome C. CytC has contrasting functions; one promoting cell survival, one 
promoting cell death. It is a soluble protein and is the only non-integral component of the 
electron transport chain. CytC acts as an electron carrier from complex III to complex IV, 
the rate-limiting step in the respiratory chain. Under certain circumstances, CytC can bind 
to CL, which prevents its own ability to participate in electron transfer. This binding 
converts CytC to a peroxidase that oxidizes CL, which in turn causes CytC to dissociate 
from the inner MT membrane. Oxidized CL synergizes with Ca2+ to cause opening of the 
MT permeability transition pore,26,27 resulting in MT depolarization, uncoupling of 
oxidative phosphorylation and release of CytC into the cytosol, triggering the caspase 
cascade and apoptosis (Figure 1.2).     
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Figure 1.2. The role of cytochrome C and cardiolipin in mitochondrial dysfunction. 
 A) Cardiolipin (CL) is a cone-shaped phospholipid expressed exclusively on the inner MT 
membrane (IMM). Incorporation of CL into the outer leaflet of the lipid bilayer causes the IMM 
to bend, forming cristae structure. This organizes the electron transport chain (ETC) proteins into 
supercomplexes, shortening the distance between redox partners and keeps CytC closely 
associated to the IMM, resulting in increased efficiency of the ETC. B) During cellular stress, CL 
is oxidized, distorting the cristae structure, which results in decreased ATP production, increased 
ROS generation, and dissociation of CytC from the IMM. Damage to the outer MT membrane 
causes influx of Ca2+, opening of the MT transition pore (MTP), and release of CytC and other 
MT proteins into the cytosol initiating the caspase cascade, culminating in apoptosis. (Modified 
from Szeto HH, Br J Pharm, 2014 and reused with permission from John Wiley & Sons Inc.)  
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Mitochondrial dysfunction in disease and aging 
 The term mitochondrial dysfunction is often used to describe a decline in ATP 
production (bioenergetic failure) but can also refer to increased ROS production/redox 
imbalance and the pathologic events that lead to MT-mediated cell-death (Figure 1.2).28 
Failure of MT energy metabolism, cumulative oxidative stress, and MT-mediated 
apoptosis are implicated in aging and the pathogenesis of many complex diseases 
including Alzheimer’s, insulin resistance, cancer, and disuse muscle atrophy.29-31 More 
closely related to this thesis are MT-mediated diseases initiated by mechanical injury, 
including intraocular pressure-induced retinopathy in glaucoma,32 shear-induced 
atherosclerosis,33,34 and neurodegeneration following traumatic brain injury.35,36 
 
Evidence for mitochondrial dysfunction in osteoarthritis  
 MT dysfunction in established OA. Chondrocytes obtain only ~25% of cellular 
ATP from MT respiration (oxidative phosphorylation), which could explain why MT 
have received little attention in OA research. However, increasing evidence supports a 
role for MT dysfunction in chronic OA.11 Many studies have identified MT dysfunction 
in cultured chondrocytes from end-stage OA patients.11,12 For example, OA is associated 
with decreased number of chondrocyte MT and decreased ATP production.37 
Mitochondrial biogenesis is impaired in OA chondrocytes due to deficiencies in the 
metabolic biosensors AMPK and SIRT1, the main regulators of MT biogenesis.38 MT 
dysfunction is linked to late-stage OA changes including decreased synthesis of collagen 
and proteoglycans, pathologic calcification of cartilage, and upregulation of matrix 
metalloproteinases 1, 3 and 13.39-42 Mutations of mtDNA affecting MT function are 
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associated with increased incidence of knee OA.43 These studies focused on MT in 
cartilage obtained from human patients with late-stage OA, whereas the goal of the 
current work was to investigate MT dysfunction in the acute time frame after cartilage 
injury.  
 Mitochondrial dysfunction in experimental models of PTOA in vitro. There is 
mounting evidence to support the concept of MT dysfunction in the initiation and early 
pathogenesis of PTOA. Redox imbalance and apoptosis are prominent in early PTOA, 
ROS are well established early mediators of the disease,44-46 and MT-derived ROS induce 
chondrocyte death after cartilage injury.29 MT may act also as intracellular 
mechanotransducers via strain-activated release of ROS,16,47,48 a theory which is 
supported by the findings that chondrocyte compression distorts the MT network,49 and 
chondrocyte cytoskeleton dissolution prevents elevated ROS and cell death in impact-
injured cartilage explants.50,51  
 Mitochondrial dysfunction in experimental models of PTOA in vivo. Recently, in 
vitro models have investigated MT dysfunction in early-chronic cartilage overload 
models, and in chondrocytes obtained after experimental induction of OA. For example, 
MT superoxide:SOD2 imbalance was found to play a role in cartilage degeneration in a 
mouse model of OA52 and chondrocyte respiratory function was reduced 4 weeks after 
surgical destabilization of the medical meniscus in rabbits.53 Taken together, these 
findings suggest MT play a central mechanobiological role in chondrocyte death after 
impact injury, and indicate a causal link between MT dysfunction and PTOA. However, a 
comprehensive study of in situ MT function immediately after cartilage injury has not 
been performed and therefore, the role of MT in the initiation of PTOA is still unclear.12  
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Failure of chondroprotective therapies 
 There are no effective therapies to slow the progression of PTOA.9 Targeting 
downstream consequences of MT dysfunction to prevent PTOA is not a novel concept 
with several of the most promising drugs acting on MT-associated pathways of cell death 
and cartilage degradation (Figure 1.3). For example, antioxidants, such as N-acetyl 
cysteine and vitamin C, are free radical scavengers and are protective in animal models of 
PTOA,52 yet fail to provide benefit in OA patients.54-56 This is likely because they do not 
effectively penetrate cell membranes and thus fail to reach the MT matrix where ROS are 
produced.57,58 Plasma membrane stabilizers such as the polaxamer surfactant p188 are 
amphipathic molecules that intercalate into phospholipid bilayers, restore membrane 
integrity, and prevent chondrocyte necrosis by decreasing calcium influx through 
damaged cell membranes.59 P188 is superior to caspase inhibitors in prevention of 
chondrocyte death after injury, and it prevents radial expansion of apoptosis from the site 
of impact.59-61 In a lapine model of PTOA, intra-articular administration of P188 
prevented chondrocyte necrosis in the superficial layer of cartilage.60 Plasma membrane 
stabilizers have not progressed to clinical trials, possibly because of their relatively non-
specific mode of action. Ideally, to prevent the initiation and progression of PTOA after 
joint injury, drugs would act further upstream, but until recently no effective 
mitoprotective therapies were available.   
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Figure 1.3. Basic mitochondria-associated pathways linking cartilage injury to 
posttraumatic osteoarthritis.  Potential therapeutics to prevent PTOA (grey) and their likely 
sites of action. Note antioxidants and caspase inhibitors act downstream of mitochondrial (MT) 
dysfunction.   
 
 
 
 
 
 
 
 
! 13 
Therapeutic targeting of mitochondria 
 Because MT play a central role in disease and aging, they are attractive targets for 
drug therapy. However, many factors inhibit the development of MT-targeted drugs and 
currently there are no FDA-approved mitoprotective agents. Most modern drugs target 
single proteins in signaling pathways involved in specific disease processes. However, 
MT are complex, multi-compartment organelles that rely on a vast network of proteins 
and lipids to carry out and regulate ATP synthesis. Therefore, attempts to identify a 
single molecular target to improve MT function have been futile. Drug toxicity is a 
concern with MT targeted therapies due to the system complexity, tightly regulated 
processes, and vital functions. Finally, many candidate drugs are not effectively delivered 
to MT. 
 The discovery of Szeto-Schiller (SS) peptides. While attempting to synthetize µ-
opioid receptor agonists capable of crossing the blood-brain barrier, pharmacologist and 
collaborator Dr. Hazel Szeto serendipitously discovered a novel class of highly polar, 
water soluble tetrapeptides. Szeto-Schiller (SS) peptides prevent MT dysfunction, 
stabilize the inner MT membrane, improve MT bioenergetics, reduce ROS generation, 
and prevent caspase-3 activation.26 They have a unique chemical structure that confers 
unexpected biological properties.26,62-64 Although these peptides have a molecular weight 
of ~640, and a net 3+ charge, they are highly cell permeable, and concentrate over 1000 
fold on the inner MT membrane, but do not accumulate in the MT matrix. Their rapid 
transport across cell membranes is not energy dependent, does not rely on a transport 
molecule, and localization to the MT does not require the MT to be polarized. Amino 
acids of alternating polarity allow the two benzene rings to fold and shield the net + 
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charges.65 The unique properties of this class of drugs confer their ability to provide 
structural protection to the cristae by specifically interacting with cardiolipin (Figure 
1.4). By protecting cardiolipin, and modulating CytC, SS peptides optimize the efficiency 
of the electron transport chain by directly stabilizing the structure of the inner MT 
membrane, thereby preventing MT dysfunction.26 
 Clinical development of SS-31. The first SS peptide to be developed as a clinical 
therapeutic is SS-31 (MTP131, BendaviaTM, ElamipretideTM; Stealth Peptides, Newton, 
MA). SS-31 directly scavenges ROS and inhibits MT depolarization.26 SS-20 is similar to 
SS-31, but does not scavenge ROS or inhibit MT permeability transition.63 Nonetheless, 
SS-20 prevents renal ischemia-reperfusion injury in mice by improving MT 
bioenergetics.66 SS-31 is in Phase 2 clinical trials for several diseases including 
myocardial infarction, acute renal failure, and diabetic retinopathy.67 SS-31 is also 
mitoprotective after mechanical injury. It prevents mechanical ventilation-induced MT 
dysfunction, oxidative stress, and protease activation in the diaphragm of mice. 
Importantly, SS-31 treatment also prevented myofiber atrophy and contractile 
dysfunction.68 SS peptides have not previously been investigated for OA.  
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Figure 1.4.  SS-31 protects mitochondrial cristae structure.  SS-31 specifically binds 
cardiolipin, preventing oxidation of its unsaturated fatty acid tails. (Modified from Szeto HH, Br J 
Pharm, 2014 and reused with permission from John Wiley & Sons Inc.)  
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Abstract  
 The diagnosis of ankle osteoarthritis (OA) is increasing as a result of advancements in 
non-invasive imaging modalities such as magnetic resonance imaging, improved arthroscopic 
surgical technology and heightened awareness among clinicians. Unlike OA of the knee, primary 
or age-related ankle OA is rare, with the majority of ankle OA classified as post-traumatic 
(PTOA). Ankle trauma, more specifically ankle sprain, is the single most common athletic 
injury, and no effective therapies are available to prevent or slow progression of PTOA. Despite 
the high incidence of ankle trauma and OA, ankle-related OA research is sparse, with the 
majority of clinical and basic studies pertaining to the knee joint. Fundamental differences exist 
between joints including their structure and molecular composition, response to trauma, 
susceptibility to OA, clinical manifestations of disease, and response to treatment. Considerable 
evidence suggests that research findings from knee should not be extrapolated to the ankle, 
however few ankle-specific preclinical models of PTOA are currently available. The objective of 
this article is to review the current state of ankle OA investigation, highlighting important 
differences between the ankle and knee that may limit the extent to which research findings from 
knee models are applicable to the ankle joint. Considerations for the development of new ankle-
specific, clinically relevant animal models are discussed.  
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Introduction  
 Post-traumatic osteoarthritis (PTOA) develops secondary to joint trauma, with clinical 
signs of pain and dysfunction often lagging years or decades behind the initiating injury.1,2 By 
conservative estimates, approximately 12% of patients with symptomatic osteoarthritis (OA) had 
a traumatic incident to their joint as the inciting cause. This corresponds to roughly 5.6 million 
Americans affected by PTOA severe enough to be evaluated by an orthopedic surgeon.3  
 Specifically in the talocrural (TC; ankle) joint, trauma is the primary cause of OA. Unlike 
the knee and hip joints, where only 2-10% of OA is attributed to injury, up to 90% of arthritic 
change in the ankle is post-traumatic in nature.2-6 The ankle is the most commonly injured joint 
during sport activities, with >300,000 injuries per year reported in the US, and an estimated 52.3 
ankle injuries per 1000 athletic exposures in high school-aged athletes.7 Ankle sprains are also 
the most common non-combat related injury with a 15% incidence rate in over 4000 military 
personnel evaluated.8 The true incidence of ankle sprains is likely much higher than reported; 
one prospective observational study of 10,393 basketball players found that over half of ankle 
injuries went unreported and were not treated by a healthcare professional.9 Individuals with a 
history of ankle sprain comprise 70-85% of patients undergoing surgery for end-stage ankle 
PTOA.10 The economic burden associated with ankle OA is demonstrated by the estimated 4400 
total ankle replacements and 25,000 ankle fusions performed in the USA in 2010.3,4 
Additionally, patients with ankle PTOA are an average of 14 years younger at the time of 
diagnosis and progress more rapidly to end-stage disease compared to those with OA of other 
joints, resulting in increased duration of pain, loss of function, and associated economic burdens 
to society.3,6,11 These data collectively indicate that the incidence, as well as the aggregate 
treatment costs of ankle PTOA will increase as the population ages.  
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 Currently, no effective therapeutics are available to prevent or slow the progression of 
OA,12 and increasing evidence suggests that interventions must occur early in order to modify 
the course of disease.13,14 Studies of PTOA present a unique opportunity for investigating 
targeted therapy, because unlike other forms of OA (e.g. idiopathic), PTOA has a defined start 
point. Likewise, in the pursuit of effective OA therapies, modeling PTOA enables the study of 
very early cellular and subcellular events that initiate and perpetuate cartilage degeneration. 
Despite the high incidence of ankle trauma and OA, ankle-specific OA research is sparse, with 
the majority of clinical and basic research pertaining to the knee and hip joints. A recent meta-
analysis of risk factors associated with OA of the lower limb identified only 2 of 43 studies 
related to the ankle.2 
 Increasingly, evidence reveals fundamental differences in cartilage structure and biology 
between joints, suggesting distinct mechanisms of disease.5,14-27 For example, a recent study 
found significant differences in the rate of extracellular matrix turnover and collagen 
composition in knee versus hip OA.28 Therefore, research findings from other joints may not be 
applicable to the ankle. However, few ankle-specific preclinical models of PTOA currently exist. 
This gap may hinder progress in the study of pathomechanisms of talocrural OA as well as the 
development of therapeutic interventions to prevent the initiation and progression of PTOA. 
Therefore, the objectives of this article are to review ex vivo and in vivo (animal model) ankle-
related PTOA research, to assess the extent to which currently available models may be 
applicable to the ankle joint, and to discuss considerations for the development of more 
translational models of ankle PTOA. 
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Etiology of Talocrural OA - The association between cartilage injury and PTOA 
 Of the 70-90% of ankle OA classified as posttraumatic, the most commonly reported 
inciting events are severe sprain and intra-articular fracture.1-3,6,29,30 Chronically altered joint 
mechanics, including malalignment, instability, and incongruity are widely accepted as 
contributory factors in the development of ankle PTOA.4,6,30-34 The relative importance of these 
chronic abnormal loading conditions versus acute mechanical trauma to the articular surface at 
the time of injury remains unclear, and likely varies between ankle injury types.33 For example, 
one group found that elevated joint contact stresses from residual incongruity after repair of tibial 
plafond fractures could predict the development of POTA in patients.35 On the other hand, 
increasing evidence suggests the magnitude of injury to articular cartilage during initial trauma is 
the major predisposing factor in ankle PTOA development.13,36 For example, concomitant 
cartilage lesions are identified arthroscopically in 63-79% of acute ankle fractures.37,38 Although 
it is difficult to deconvolve chondral injury from fracture grade, long-term follow up of 109 
ankle fracture patients found that initial cartilage damage is an independent predictor for the 
development of both clinical and radiographic PTOA.39  
 The importance of acute cartilage injury in the etiology of ankle OA is particularly 
evident for sprain-associated PTOA. During a typical severe ankle sprain, the medial tibial 
plafond is thought to impact the medial aspect of the talar dome, resulting in a talar 
osteochondral lesion (Figure 2.1). This mechanism of injury is supported by the anatomic 
distribution of talar osteochondral lesions (OCLs), with the medial talus affected nearly twice as 
frequently as the lateral talus, and the mid-one third of the talar dome affected 4 times more 
commonly than the anterior and posterior thirds combined.40 Evidence suggest that the majority 
(as high as 95%) of severe ankle sprains result in OCLs and over half of patients with OCLs  
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Figure 2.1.  The proposed mechanism of posttraumatic osteoarthritis after a severe ankle sprain.  
A) During a typical lateral ankle sprain (inversion) the medial aspect of the talus likely impacts the tibial 
plafond which may result in B) a talar osteochondral lesion (OCL).  Direct trauma to the articular surface 
can initiate progressive, irreversible joint destruction culminating in C) late-stage posttraumatic 
osteoarthritis (PTOA) years to decades after the original injury.    
 
 
 
 
 
 
 28 
develop OA.41,42 Ligament injury resulting in chronic ankle instability is a common sequelae to 
severe sprain, and approximately 15% of ankle sprains are recurrences.43 However, instability 
alone cannot account for the incidence of resulting PTOA.10 In a population of patients 
presenting to orthopedic surgeons with severe ankle OA, approximately equal numbers of 
patients reported a single ankle sprain as those reporting recurrent sprains (i.e. chronic 
instability).3 Notably, one study reported that the mean latency time between injury and end-
stage OA was 12 years shorter for patients who suffered a single ankle sprains than those who 
experienced chronic recurrent sprains. The authors speculate that the more rapid progression of 
PTOA in patients without chronic joint instability could be explained by the degree of cartilage 
damage sustained at the time of injury.11 Finally, no clinical study to date has demonstrated that 
any conservative or surgical therapies to stabilize the ankle joint after injury decrease the 
incidence of PTOA, further suggesting that the magnitude of the initial cartilage/subchondral 
bone injury is the primary inciting cause of ankle PTOA.10,44-47  
 In patients presenting for ankle pain, MRI is the imaging modality of choice because of 
its ability to identify ligamentous injury, subchondral bone edema, and cartilage pathology.48-50 
However, diagnosing subtle talar cartilage lesions and the early phases of PTOA remains 
challenging.45 In one study, 107 ankles in 101 patients (mean age 28.7 years) with chronic lateral 
ligament instability secondary to ankle sprain were examined arthroscopically to assess the 
articular cartilage prior to ligament reconstruction. In 99 ankles without abnormalities diagnosed 
on radiographs or MRI, 77% had chondral lesions identified during arthroscopy.51 In a recent 
study, 3T MRI of the ankle joint had a reported 71% sensitivity and 74% specificity for detecting 
talar dome articular cartilage defects (Outerbridge grades 3 and 4) that were confirmed on 
arthroscopy.49 A similar study reported a sensitivity of only 46% for the diagnosis of talar OCLs 
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on 1.5T MRI.50 In one cohort of young, active individuals who had experienced an ankle sprain 
within 5 years of evaluation, T2 relaxation times were increased in injured ankles with and 
without instability relative to uninjured controls, indicating early subclinical cartilage 
degeneration.48 These findings suggest that while diagnostic imaging modalities continue to 
improve, the incidence of chondral lesions and early PTOA may be higher than previously 
recognized.  
   
Differences between the ankle and knee joint  
 Differences between the ankle and knee, summarized in Table 2.1, are important 
considerations when extrapolating clinical or basic OA research knowledge of the knee to the 
ankle. Overall, the knee has an approximately ninefold higher incidence of clinical OA than the 
ankle, however the proportion of PTOA is at least sevenfold higher in the ankle.3 Improved 
understanding of the biological and mechanical factors underlying this disparity may contribute 
to the development of joint-specific therapies. 
 
Differences between ankle and knee joint anatomy and biomechanics  
  The articular surfaces of the talocrural joint are highly congruent resulting in intrinsic 
stability of the ankle based on bony anatomy alone52 (Figure 2.2). Furthermore, during weight-
bearing, redistribution of contact stresses over the tibiotalar articular surfaces increase ankle joint 
stability.52 Only at the extremes of the normal range of motion is stability of the ankle joint 
maintained by soft tissue structures including the anterior and posterior tibiofibular ligaments 
and the calcaneofibular ligament.53 In contrast, the rounded femoral condyles are  
 
 
 30 
 
 
Table 2.1.  Summary of important differences between the knee and ankle joints.  The ankle 
has a low prevalence of primary OA, but a high proportion of PTOA. The ankle joint is more 
congruent and has higher intrinsic stability than the knee. The extracellular matrix (ECM) 
properties of ankle cartilage may protect against primary OA and ankle chondrocytes may also 
have improved homeostatic mechanisms compared to that of knee chondrocytes. OA = 
osteoarthritis, sGAG = sulfated glycosaminoglycans, PG = proteoglycan, CII =type II collagen, 
IL-1 = interleukin-1, Fn-F = fibronectin fragments.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Ankle  Knee 
Prevalence of primary OA Low Higher (ninefold) 
Proportion of OA secondary to trauma High (80%) Low (10%) 
Anatomy and Mechanics     
  Joint congruity High  Low 
  Articular contact area Low High 
  Cartilage thickness Thin (0.7-1.62mm) Thick (1.5 -2.6mm) 
  Cartilage stiffness (Compressive modulus) High Lower 
ECM properties     
  sGAG content Higher (twofold) Lower 
  Water content Lower Higher 
  Collagen content No difference Similar 
Metabolism     
           Basal PG synthesis and turnover High Low 
Response to mechanical loading     
  Upregulation of collagen synthesis marker (CII) Yes No 
  Upregulation of aggrecan mRNA Yes No 
Response to catabolic signals      
  Net response Anabolic Catabolic 
  IL-1 inhibition of PG synthesis Low Higher (eightfold) 
  IL-1 induced PG degradation No Yes 
  Fn-f induced PG loss Low High (30-50% loss)  
 31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.  A comparison between the knee and ankle joints.  The contact surface area of knee joint is 
approximately three times larger than the ankle. The ankle has more bony congruity than the knee, and is 
therefore less reliant on supporting soft tissues (pink-purple) to maintain stability. Ankle cartilage (blue) 
is approximately half the thickness of knee cartilage, although the superficial zone thickness is similar 
between joints. The extracellular matrix of ankle cartilage is more dense than that of the knee and has a 
higher dynamic stiffness and compressive modulus.  
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incongruent with the flat surface of the tibial plateau, making the knee joint highly reliant on soft 
tissues such as menisci, collateral ligaments, and cruciate ligaments, to maintain stability during 
loading.54 The motion of the ankle joint is “rolling” with the center of rotation changing 
throughout a range of motion of 50 degrees plantar flexion to 20 degrees of dorsiflexion. The 
point of articulation is slightly oblique to the long axis of the tibia resulting in a slight (~3 
degree) valgus conformation and an outward deviation of the foot with dorsiflexion and inward 
deviation with plantar flexion.55,56 In contrast, the normal motion of the knee joint is a 
combination of sliding, rolling, and rotation.54   
 The articular cartilage in the ankle is approximately half the thickness of knee cartilage 
(Figure 2.2), with a mean thickness of 0.7 - 1.62mm in the ankle versus 1.5 - 2.6mm in the 
knee.57,58 The relatively smaller size of the ankle joint results in a contact surface area 
approximately one-third that of the knee, which translates to higher force per area (stress) during 
loading.59 In plantar flexion, the contact area of the ankle joint decreases by greater than 40% 
with corresponding increases in peak stresses.60 This may partially explain the high incidence of 
ankle OA in retired ballet dancers61 and early subclinical disease in a cohort of active 
professional dancers.62 During eversion and inversion, contact area also decreases, and peak 
stresses increase.60 One study estimated that with 1 mm of lateral talar displacement, as might 
occur during a typical ankle sprain, contact area of the ankle joint is decreased by 42%.63 A 
computer simulation modeling study found that plantar flexion and inversion during forefoot 
loading increases the likelihood of ankle sprain,64 which is consistent with the high prevalence of 
sprains during jump landing in the sport of basketball.65 Accidental sprains incurred by subjects 
during controlled laboratory testing consistently accompanied internal rotation and rapid 
inversion, with or without plantar flexion.10   
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Differences between ankle and knee cartilage extracellular matrix properties and chondrocyte 
distribution 
 The extracellular matrix (ECM) of articular cartilage, comprised mainly of proteoglycans 
and type 2 collagen, functions in load bearing and supports near-frictionless joint movement. In 
the ankle, the ECM is more dense than that of the knee, with lower water and higher 
glycosaminoglycan (GAG) concentrations.16 In compression, ankle cartilage has a higher 
dynamic stiffness and compressive modulus than knee cartilage16 (Figure 2.2). These physical 
properties of ankle cartilage translate to an increased resistance to compressive loads, but do not 
necessarily explain why the ankle might be more resistant to mechanical damage than the knee. 
Recently, increased attention has been directed toward resolving depth-dependent mechanical 
properties of articular cartilage, revealing that the superficial layer is more compliant (lower 
compressive stiffness) and dissipates more shear energy than the deeper tissue.66-68 For example, 
the superficial 500um of the articular surface has a shear modulus 2 orders of magnitude lower 
than that of the deep zone, and acts to dissipate nearly 90% of shear energy.69 Although ankle 
cartilage is roughly half as thick as knee cartilage, the superficial zone thickness is similar 
between joints, therefore the superficial zone comprises a relatively higher proportion of 
cartilage in the ankle than the knee (Figure 2.2). This relative difference has been suggested to 
play an important protective role during physiologic loading in the ankle,16 and could have 
important implications in the development of ankle-specific therapies.   
 Chondrocytes are the sole cell type within articular cartilage and are responsible for 
maintaining the surrounding ECM.70 Cell density in full thickness ankle cartilage (41 ± 34x103 
cells/mg) has been reported to be 48% higher than knee cartilage (28 ± 26 x103 cells/mg).19 
Interestingly, the spatial organization of superficial zone chondrocytes differ between the ankle 
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and knee joints, and the understanding of these differences have evolved with improved imaging 
techniques.71,72 In the human ankle joint, superficial zone chondrocytes are predominantly 
arranged in pairs, but in the in the femoral condyles of the knee, they are arranged in horizontally 
oriented strings. These distinct patterns are likely related to predominant collagen fiber 
orientation within the superficial zone, but it remains unclear if they are causally linked to local 
biomechanical forces or have implications in chondrocyte function or mechanotransduction. 
These predictable patterns of organization in the superficial zone chondrocytes change in early 
OA, both within areas of focal OA and in intact cartilage remote to focal lesions, indicating a 
coordinated response of chondrocytes to injury, and may serve as sensitive indicators of early 
preclinical OA and/or focal cartilage lesions elsewhere in the joint.72,73   
 
Differences between ankle and knee cartilage matrix homeostasis and response of chondrocytes 
to biochemical and mechanical stimulation 
 In matched pairs of ankle and knee cartilage from healthy cadaver joints, ankle 
chondrocytes had increased proteoglycan (PG) and collagen synthetic rates compared to knee 
chondrocytes, and these differences persisted throughout life.18,19 In diseased cartilage with 
surface fibrillations and fissuring consistent with early OA, markers of collagen synthesis (CPII) 
and aggrecan turnover (epitope 846) are increased in the ankle, but down-regulated in the knee. 
Markers consistent with collagen degradation (Col2-3/4C short) are higher in the knee than the 
ankle.25 These findings may explain the observation that age-related degeneration of the ECM 
does not occur in the ankle, or it happens at a much slower rate than in the knee.17  
 Ankle and knee cartilage also differ in their response to catabolic signals. Knee 
chondrocytes are approximately eight times more sensitive to inhibition of PG synthesis by the 
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catabolic cytokine interleukin-1 (IL-1).18 The ankle is also less susceptible to fibronectin 
fragment (Fn-f)-mediated degradation.21,74 PG content was decreased by 30-50% in knee 
cartilage exposed to Fn-f for two weeks, whereas it was essentially unaffected in ankle cartilage 
after FN-f exposure for a month.74 
 More specifically with respect to PTOA, differences between ankle and knee cartilage are 
evident in their disparate response to injurious compression. In adult knee cartilage, injurious 
compression (65% fixed strain, 2 mm/s fixed velocity, strain rate approximately 400%/s) resulted 
in matrix damage in 46% of samples and a net loss of about 1.2% of total GAG in knee explants. 
Ankle cartilage subjected to the same magnitude of injury sustained little damage and no GAG 
loss, suggesting that ankle cartilage is more resistant to mechanical injury.22 An approximately 2-
fold increase in aggrecan mRNA expression was observed in knee versus ankle chondrocytes in 
response to mechanical stimulation. Ankle chondrocytes express higher levels of integrin-
associated proteins CD98, CD147 and galectin 3 than knee chondrocytes, suggesting differences 
in integrin-associated mechanotransduction and matrix remodeling.75 Collectively, these data 
suggest that ankle chondrocytes have superior homeostatic mechanisms compared to knee 
chondrocytes.  
 Despite this convincing body of literature indicating ankle chondrocytes are inherently 
more anabolic and less catabolic than knee chondrocytes, there is also interesting evidence to 
suggest otherwise.  No differences in the synthetic capabilities or response to catabolic stimuli 
were detected in pellet cultures of chondrocytes from the ankle and knee of the same 
individual.76 In this study, chondrocytes from both joints were similar in expression of type 1 and 
type 2 collagen mRNA. Pellet ECM contained equivalent concentrations of GAG and type II 
collagen and the synthetic rates of GAG and collagen were similarly decreased in response to IL-
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1 treatment.76 These findings suggest that characteristic differences between ankle and knee 
chondrocytes are lost once the cells are isolated from their native ECM and expanded ex vivo, 
implying that the native tissue environment may be more important in dictating the characteristic 
properties of ankle and knee chondrocytes than intrinsic differences between cell types.  
 Taken together, these findings suggest that major differences exist between joints, which 
are likely to influence disease pathomechanisms and affect clinical response to OA therapies.  
Therefore, ankle-specific and injury-specific modeling of PTOA may accelerate progress in basic 
and clinical research.   
 
Ex vivo ankle cartilage injury models 
 In addition to the cartilage injury models mentioned above, several groups have used 
explanted ankle cartilage to investigate early disease mechanisms and response to therapeutic 
interventions. For example in one model, fresh cadaveric human tali were subjected to a single 
pressure-controlled impact injury (1Ns; up to 600N within 2ms).77 Explants were removed from 
the bone and cultured for up to 2 weeks. Chondrocyte viability was assessed using live-dead cell 
staining and apoptosis was assessed using a Tunnel assay. Histopathology was performed and a 
Modified Mankin score was used to assess cartilage injury. Explants were treated 1 hour prior to 
injury or 48 hours after injury with one of 3 cytoprotective drugs. The polaxamer surfactant 
P188, a plasma membrane stabilizer, was found to be superior to caspase-3 and caspase-9 
inhibitors in preventing impact-induced chondrocyte death and the radial expansion of apoptosis 
from the site of impact. 
 A major strength of these types of ex vivo models is that they allow injury-induced 
cellular responses to be studied in situ (i.e. in chondrocytes within their native extracellular 
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matrix) immediately after cartilage injury, and over time.78 Additionally, ex vivo models allow 
preliminary testing of putative early interventional therapies.79 A drawback of ex vivo models is 
that they fail to capture important aspects of disease pathogenesis including the inflammatory 
response, joint loading conditions, etc. Therefore, in vivo analogs of these injury- and joint-
specific ex vivo models are important for preclinical testing of therapeutics. 
 
Non-traumatic animal models of ankle osteoarthritis 
 Several non-traumatic rodent models of ankle OA have been published. These models 
utilize the ankle joint to investigate cartilage degeneration secondary to acute joint inflammation, 
joint immobilization or spontaneous/age-associated OA.  Despite limitations in the translatability 
of these models to clinical ankle PTOA, they may serve as useful tools to explore specific 
aspects of ankle OA pathophysiology. Furthermore, several of these studies have directly 
compared the ankle and knee joints within the same individual, and will therefore be reviewed.  
  
 Intraarticular IL-1β model of acute ankle inflammation in rats.  Scott, et al. described 
injection of IL-1β into the ankle of rats as an acute model of joint inflammation.80 Biochemical 
changes in joint lavage fluid, gene expression changes in whole joint tissues, and histopathology 
were assessed up to 24 hours after injection. They found that 100ng of IL-1β caused joint 
swelling and hyperalgesia, as well as gene expression of pro-inflammatory and catabolic 
mediators, including IL-6, PTGS2, NOS2, TNFα, NFκB, ADAMTS5 and IL-1β. Biochemical 
analysis of joint lavage fluid revealed accumulation of GAG, IL-6 protein and NO. 
Histopathology at 24 hours showed evidence of synovitis. Although there was no histological 
evidence of cartilage destruction in this short time frame, the release of GAG into joint lavage 
fluids likely indicates early ECM degradation. Strengths of this model include the induction of 
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reproducible joint inflammation and GAG release within 4 hours. This model is potentially 
useful for the initial evaluation of antagonists of the IL-1 pathway. The utility of this model is 
limited by the short study duration and non-physiologic method of disease initiation.   
 
 Short-term ankle immobilization model of cartilage atrophy in rats.  Renner, et al. 
evaluated the effect of a passive muscle stretching protocol on the articular cartilage of normal 
and previously immobilized rat ankles.81 One ankle in each mouse was immobilized non-
invasively for four weeks and histology was performed at 7 weeks. Unilateral ankle 
immobilization caused increased cellularity and chondrocyte cloning in both the immobilized 
and non-immobilized limb over control animals. Similarly, proteoglycan depletion was present 
in both limbs of unilaterally immobilized mice, worse in the immobilized than the contralateral 
limb. No differences in cartilage thickness were observed.  
 When passive muscle stretching was instituted for 3 weeks following remobilization, 
higher cellularity was observed in treated ankles of the stretched group and chondrocyte cloning 
was observed in the contralateral limb. Notably, immobilized/stretched ankles had the highest 
PG loss of all the groups calling into question the utility of this modality or the methodology by 
which it was employed in this model. This model may be useful to investigate therapies to 
prevent cartilage atrophy following ankle immobilization, and in combination with an ankle 
destabilization model, could possibly provide insight into the relative importance of joint 
immobilization in the degenerative and healing processes after destabilizing ankle injuries.    
 
 Spontaneous ankle OA model in guinea pigs. Han, et al. were the first to report OA-like 
lesions occurring spontaneously in the guinea pig ankle.82 They performed histologic 
examination and assessed collagen fiber orientation in knee and ankle pairs from male Dunkin-
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Hartley guinea pigs at 3 and 6 months of age. Changes in the ankles were evenly distributed 
between the tibial and talar joint surfaces. At 3 months of age, synovitis was present in all ankle 
joints and mild focal degenerative cartilage changes were present in some ankles, but histologic 
scores were not different than controls. At 6 months, moderate focal cartilage lesions, 
chondrocyte loss and loss of PG staining were present in all ankles. While ankle joint scores 
were only elevated at 6 months, knee joint scores were significantly elevated at 3 and 6 months. 
In areas of intact cartilage, changes in collagen fiber orientation were identified and correlated to 
PG loss indicating that remodeling of the ECM plays a role in early disease and may precede 
histologic changes this model of spontaneous OA. 
 
 STR/ORT mouse model of spontaneous ankle OA. The STR/ORT mouse is a well-
established model of spontaneous knee OA, and its utility has been reviewed.83 Males are 
preferentially affected, and early calcification of periarticular soft tissue structures is a prominent 
feature of this model. Evans, et al. described the radiographic changes and Collins, et al. 
described the histopathological changes in the knees and ankles of STR/ORT mice from 3-10 
months of age.84,85 The radiographic progression of OA in knee and ankle joints was different; in 
male mice, knee OA worsened directly with age, whereas ankle OA scores increased markedly at 
5-6 months, then plateaued. Histology revealed extensive new bone formation in the entheses 
around the ankle and mineralization of the talar interosseous ligaments starting around 3 months 
of age. The development of knee and ankle OA was found to be independent within a single 
mouse.  
 The etiology of OA in STR/ORT mice is not entirely clear but recently, meta-analysis of 
transcription profiles revealed increased expression of genes related to endochondral ossification, 
increased MMP-13 and type X collagen expression as well as differential expression of 
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regulators of tissue mineralization, suggesting an inherent chondrocyte defect related to 
endochondral growth.86 The excessive soft tissue calcification, which precedes cartilage 
degeneration in this model suggests that the pathophysiology is unlikely to be reflective of 
human ankle OA.83,87  
  
 BCBC/Y mouse model of anklylosing ankle OA. Yamamoto, et al. described a mutant 
B6C3F1 mouse with a light coat color displaying progressive ankle swelling starting at around 9 
months.88 By 10-20 months, these mice display an abnormal stance and gait, with progressive 
ankylosis of the tarsus on radiographs. On histologic examination, early cartilage lesions 
included chondrocyte necrosis, cartilage fibrillation and thinning. Later changes included full-
thickness erosions in conjunction with a hyperplastic cartilage response.89 Severe osteophyte 
formation progressed to bridging ankylosis and finally complete joint fusion of the tarsal joints. 
Despite these dramatic changes, no synovial inflammation was identified. There is a strong sex 
predilection, with 87% of males affected and 21% of females. The disease mechanisms and 
underlying genetic basis of this atypical arthropathy, with a strong predilection for the ankle 
joints has not been identified.   
  
 Aging model of ankle OA in rats. Although spontaneous knee OA is rarely reported in 
rats,90,91 Mohr and Lehman describe spontaneous ankle OA in 26 month old CD/BR Sprague 
Dawley rats.92 Histology was performed on the talocrural and subtalar joints and morphologic 
changes were scored semi-quantitatively on a 40-point scale. Lesions ranged from focal 
chondrocyte necrosis, to loss of proteoglycan staining to fibrillation to partial and total loss of 
hyaline cartilage to full thickness lesions involving the calcified cartilage layer. Synovitis was 
rarely present. Although disease mechanisms were not investigated, changes were commonly 
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present on opposing articular surfaces, suggesting localized increased contact pressures may play 
a role. Males had more severe lesions compared to females, which could be related to 
mechanical factors due to the higher body weight of males and/or endocrine factors.  
 This model was subsequently used to study the effect of meloxicam, a non-steroidal anti-
inflammatory drug, on ankle OA.93 While no drug effect was found, this study demonstrated that 
the incidence and severity of OA changes are highest in the ankle compared to the hip and knee 
joints in this model. A consideration in the application of this model is that in humans, age-
associated cartilage degeneration in the knee is consistently more severe than in the ankle of the 
same individual.26,94 A limitation of any of these spontaneous models of ankle OA is that in 
humans, primary ankle OA is uncommon.  
 
Modeling ankle posttraumatic osteoarthritis in vivo 
 Many preclinical PTOA models are available and have been well reviewed.95-102 
Appropriate use of existing models and the development of preclinical models with improved 
translatability is an ongoing topic of discussion within and beyond the field of OA research.103-105 
The majority of in vivo PTOA models utilize the knee joint, but the numerous anatomical, 
biomechanical, and biochemical differences between the ankle and the knee suggest that an 
ankle-specific model is appropriate when targeting therapy for ankle OA.  Recently, two 
surgically induced models of ankle OA have been described. 
 
 Destabilization models of ankle OA in the mouse. Recently, Change et al. described an 
aging model, as well as three destabilization models of mouse ankle OA.106 First, ankle and knee 
cartilage from 25 month-old mice were compared to cartilage obtained from humans undergoing 
joint replacement surgery. OARSI scores for tibiotalar cartilage were lower than for the medial 
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compartment of the knee, indicating the mouse ankle is more resistant to age-associated cartilage 
degeneration than the knee, similar to humans. They also found that like humans, mouse talar 
cartilage is approximately half as thick, and talar subchondral bone was denser compared to the 
medial tibial plateau. This serves as an important baseline reference, and indicates that this 
model may have better translatability for the study of age-related ankle OA than those previously 
mentioned. One caveat to the interpretation of these findings is that normal, aged mouse tissues 
were compared to cartilage from end-stage OA joints in humans.   
 The authors go on to describe three methods of ankle joint destabilization in young mice. 
The medial model involved transection of the tibialis posterior tendon and deltoid ligament and 
incision of the medial joint capsule. This technique resulted in progressive cartilage degeneration 
in the talocrural joint over the 8 weeks following surgery. Increased MMP-13 and ADAMTS5 
were detected on immunohistochemistry and chondrocyte apoptosis was identified on TUNEL 
staining. A lateral destabilization model resulted in subtalar OA changes, while a bilateral model 
resulted in both talocrural and subtalar OA.  
 The major strengths of the medial destabilization model is that it captures many 
important features of human disease, including progression of tibiotalar cartilage lesions, 
chondrocyte apoptosis and inflammatory cytokines, and also lacks the excessive osteophyte 
formation present in other mouse models. The differences in disease phenotype induced by the 
three surgical techniques highlights the importance of increased specificity in the type of injury 
used to study PTOA subtypes. In humans, injury to the lateral soft tissues are more commonly 
associated with ankle sprain and OA.107,108 In the mouse, complete transection of the major 
lateral stabilizing soft tissues and invasion of the joint capsule did not result in significant 
talocrural joint OA.  
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 Intraarticular fracture model of ankle OA in the Yucatan miniature pig. Goetz, et al. 
recently developed a porcine distal tibia intraarticular fracture/stabilization model to assess the 
effects of poor anatomic reconstruction on the development of ankle PTOA.109 Fractures of the 
distal tibia were created using an open joint approach and repaired using internal fixation with a 
bone plate. Synovial fluid analysis, radiographic monitoring and force plate analysis were 
performed after surgery and animals were sacrificed at 12 weeks. Osteochondral histology was 
performed and scored using automated Mankin scoring. By 12 weeks post-operatively, all 
fractures were healed and limb loading had returned to normal. Inflammatory cytokine 
concentrations in synovial fluid, including TNFα, IL1β, IL6, and IL8 were elevated transiently 
during the 2 weeks after fracture. Histology scores were worse in joints with articular 
incongruity compared to those that were anatomically reconstructed.  
 This is a well-validated model to investigate intraarticular fracture-induced PTOA and 
the effects of chronically altered ankle joint mechanics due to articular surface incongruity.  
Strengths of this model include a consistent fracture geometry, with reporting of the energy 
absorbed during fracture, and clinically relevant outcome measures including intra- and post-
operative imaging and analysis, gait analysis to quantify pain/joint dysfunction, synovial fluid 
biomarkers and osteochondral histology, although synovial membrane was not assessed. Internal 
fixation techniques are similar to those used in human clinical patients. In this report, 27% (6/22) 
of the animals were lost post-operatively due to orthopedic complications. Longer-term follow 
up will be required if this model is to be used to test biological treatments to reduce the incidence 
of fracture-associated ankle PTOA.  
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Considerations for development of new preclinical models of ankle PTOA 
 
Method of OA induction 
 When modeling PTOA, the induction method would ideally mimic that of naturally 
occurring disease. The majority of PTOA models utilize the knee (stifle) joint and rely on 
surgical destabilization of supporting soft tissue such as the meniscus or anterior cruciate 
ligament.95-100 PTOA models involving joint instability or the generation of an osteochondral 
fragment are valuable tools, however these models do not reflect the contributions of acute 
trauma to the articular cartilage at the time of injury. Although the specific injury parameters 
required to initiate clinical PTOA remain unclear, these mechanical thresholds have been studied 
in many model systems, and experimental evidence supports the importance of loading 
magnitude and rate as predictors of cartilage degeneration.13,22,31,110-113  
 To more specifically investigate mechanical overloading of the articular surface, single-
impact load models are becoming more prevalent in PTOA research, and have been validated to 
initiate early OA-like lesions in the knee, but have not been applied to the ankle.114-116 This 
reductionist approach allows investigators to gain new insight into the cartilage-specific 
contributions to PTOA ex vivo, investigate mechanical thresholds for peracute cellular and 
subcellular responses to cartilage injury, and test targeted drugs to prevent PTOA in animal 
models. For example, a recent study examined microscale mechanics and corresponding 
chondrocyte death in articular cartilage following rapid impact injury.117 This new technique 
revealed that chondrocyte death is highly correlated with a threshold of 8% microscale strain. 
When the superficial layer of the cartilage was removed, cell death penetrated deeper into the 
cartilage, indicating a protective role for the superficial layer. Additionally, chondrocyte death 
developed within 2 hours of impact, suggesting a narrow window for early therapeutic 
 45 
intervention after injury.117 In summary, an overly aggressive model with rapid progression to 
end-stage OA may not provide a sufficiently dynamic range of disease to evaluate therapeutic 
effects in a preclinical ankle model and a single, rapid impact model is most consistent with the 
likely etiopathogenesis of ankle PTOA. 
 
Species Choice  
 Rodent models have the advantages of being low cost, genetically similar within a 
specific breed strain, and amenable to genetic manipulation. Rodent models have therefore been 
used extensively as screening tools for drug development and to investigate specific molecular 
pathways involved in OA pathogenesis.95,96,99,102,118,119 The most significant shortcomings of 
small animal models are the dissimilarities in cartilage structure and disparate loading compared 
to a human joint. An optimal preclinical model would be scaled appropriately to mimic joint size 
(Figure 2.3), load, age and skeletal maturity of human clinical patients. The cartilage lesion 
should be located in an analogous location in ankle, and be of similar size, type and depth as 
clinically observed lesions, which is difficult or impossible to control in rodents. Recently, a 
mouse model of ankle OA was described based on surgical destabilization.106 Rabbit models are 
slightly larger and have been used in single impact studies of knee PTOA without the 
confounding variables of instability.114,120   
 Common large animal species used in OA research include the dog, sheep, goat, pig and 
horse.95,99-101,104,116,121-124 A benefit common to these larger species is increased joint size, 
allowing OA outcome measures such as synovial fluid collection, clinical cartilage imaging 
modalities including MRI, quantitative gait analysis, arthroscopic joint examination, 
topographical evaluation within a single joint and ample tissue for histological, biochemical,  
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Figure 2.3. Comparative talus anatomy. Size comparison of left tali from species commonly used as 
animal models in osteoarthritis research; A) horse, B) pig, C) sheep, D) dog, E) rat, F) mouse, compared 
to the G) human. 
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biomechanical, and molecular analyses. Large joint size is a particularly important feature if 
precise anatomical placement of articular surface trauma is to be employed. 
 The dog knee has been widely used in preclinical models of knee OA, therefore validated 
outcome measures have been established in that joint.99,123 Most commonly, OA is induced by 
surgical destabilization, however single impact models have recently been described.116 Dogs are 
an athletic species and are prone to naturally occurring OA, however as a popular companion 
animal species, their use in biomedical research draws heightened scrutiny by the public. Sheep 
and goats have been used in several destabilization models of knee OA as well as a femoral 
condyle impact model.125 Sheep and goats have joints that are closer in size to the human ankle 
than dogs (Figure 2.3), however naturally occurring OA is rare to non-existent, and these species 
may be less susceptible to OA after surgical induction, as ACL transection leads to joint 
instability but not significant OA in the goat knee.122,126 When considering the development of 
preclinical models, small ruminants (sheep and goats) have the particular disadvantage of being 
foregut fermenters, and therefore bioavailability of orally administered therapeutics differ 
significantly from monogastric species (i.e. humans, horses, dogs, pigs).     
 The horse is an established model organism for PTOA research and offers several 
advantages over other species. The horse is the largest model available and equine cartilage most 
closely approximates human cartilage thickness and biomechanical loading.127,128 Similar to 
humans, the cartilage of the equine talocrural joint has a higher GAG content, and is stiffer than 
that of the knee.129 The equine species is naturally prone to OA.130 Similar to the human ankle, 
the equine TC joint has a high degree of intrinsic bony stability and rarely suffers OA in the 
absence of injury.131,132 As in humans, equine TC PTOA does occur secondary to ligamentous 
injury, blunt trauma, OCLs and intraarticular fractures.131-133 The dimensions of the equine 
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talocrural joint are well suited to arthroscopic examination and manipulation and it is among the 
most common arthroscopically approached joints in equine surgical practice. In addition to the 
potential to perform serial arthroscopic examinations, MRI is a well validated diagnostic 
modality to assess the equine TC joint, therefore the horse may be considered for studies where 
longitudinal evaluations of cartilage are needed.134-136  
 
Outcome measures 
 Histopathology remains the gold standard for assessing OA progression. Many systems 
have been used to evaluate OA changes, and these have been extensively reviewed.137 
Commonly used scoring systems in animal research models are the Mankin Score,138 the OARSI 
scoring system 139and the ICRS score for cartilage repair.140 Recently, species-specific consensus 
scoring systems have been developed for the most important species used in OA research 
including dog, guinea pig, horse, mouse, rabbit, rat, and sheep/goat.101 To reduce the number of 
animal sacrifices at each time point, longitudinal outcome assessments are preferred, including 
imaging, biochemical and genetic biomarkers, as well as assessments of pain, joint function and 
gait. Appropriate ankle-specific biomarkers will need to be identified and validated in order to 
develop translational PTOA models that more closely represent clinical subgroups of disease.141   
 MRI allows objective measures of soft tissue injuries and cartilage health in human and 
large animal veterinary patients, and its use and utility in preclinical animal models will continue 
to increase. Bone bruising is identified on MRI in 16-40% of patients after ankle sprain, and in 
up to 50% of patients with ligament injuries.142,143 Therefore, the assessment of subchondral 
bone should be included in the characterization of ankle injury models. Highly congruent joints 
with relatively thin articular cartilage are more challenging to assess using MRI, however steady 
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advancements in imaging technology have allowed evaluation of subtle cartilage lesions in the 
ankle.144,145 Contemporary compositional MRI techniques including dGEMRIC and T1-rho, and 
T2 mapping have become increasingly useful for assessing cartilage degeneration and allow 
examination of biochemical or ultrastructural composition of articular cartilage relevant to OA 
research.145,146 Combining clinical and research data pertaining to the ankle may allow 
identification of preclinical disease. As discussed, evidence in patients with ankle injuries 
suggests that, in addition to advanced imaging, arthroscopic examination is particularly 
important in identifying early ankle PTOA. Therefore, the ideal model would allow serial 
arthroscopic examination of the talocrural joint.   
 A major challenge in developing appropriate preclinical animal models of OA is the 
ability to quantify pain as a clinical endpoint. Chronic pain is a hallmark of OA, and the ability to 
evaluate pain and joint dysfunction is integral to the relevance and utility of models in 
translational research. This is especially relevant for less severe models of OA, when the goal is 
to study and develop therapies targeted at early OA in humans.104 Numerous measures of pain 
and joint dysfunction that have been developed in multiple species, and it is not clear which of 
these will prove the most useful in ankle PTOA models. As an example, gait abnormalities are 
well-established indicators for pain. In horses and dogs, quantitative gait analysis has been used 
for over two decades to evaluate naturally occurring and experimental lameness. Studies have 
employed force plate, pressure plate, accelerometers and kinematic image analysis, and these 
outcome measures are well validated.147-154 In small animal models, pain and joint dysfunction 
have been less commonly reported outcome measures, although more recently these systems 
have been developed and validated for rodents.151,155,156 Quantitative gait analysis is possible in 
pigs, sheep, and goats, however their temperament is less amenable to pain assessment using 
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standard techniques such as force plate analysis.  New mechanisms of pain are being identified in 
OA patients, and appropriate outcome measures will need to be identified as new joint-specific 
and injury-specific PTOA models are developed.104,155,157,158 
 
Conclusion 
 OA is the most common cause of chronic disability in the United States, and as the 
population ages, it will become increasingly burdensome to society. The ankle is the most 
commonly injured joint, and ankle PTOA disproportionately affects populations of young adults, 
athletes and military personnel. Laboratory and animals model studies will continue to reveal 
pathomechansisms of ankle PTOA. Remaining unmet needs related ankle OA include early 
interventional therapies (so called “point of injury care”) to prevent progression of early PTOA, 
as well as methods to treat established/late-stage OA. To address these knowledge gaps, an 
appropriate ankle-specific preclinical PTOA model would allow investigation of the early 
initiating events following talocrural cartilage injury, as well as longitudinal testing of targeted 
therapies in a clinically relevant species.  
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Abstract 
 Mechanical injury to articular cartilage causes chondrocyte death and cartilage 
degeneration in ex vivo experimental models. Clinically, ankle (talocrural) joint trauma is known 
to lead to the development of posttraumatic osteoarthritis (PTOA) in patients. The objective of 
this study was to develop a single, rapid impact, non-fracture model of talocrural PTOA.  
 For ex vivo model development and validation, osteochondral blocks of the medial 
trochlea of the equine talus were harvested and the articular surface was impacted over a broad 
range of stress magnitudes using a custom-built spring loaded impacting device. The mechanical 
relationship between peak stress and force was determined. Histology and multiphoton 
microscopy were performed to define the extent of acute cartilage damage. For the in vivo 
cartilage impact model, two cadaveric equine talocrural joints were used to develop the surgical 
approach. Then, two healthy adult horses were anesthetized and three impacts of varying 
magnitudes were applied to the left and right talus (n = 4 joints) under arthroscopic guidance. 
Postoperatively, joint fluid was obtained weekly and analyzed for evidence of inflammation and 
early degenerative change. Horses were sacrificed at 6 or 12 weeks post operatively and 
histopathology was performed on each individual impact. One normal horse (2 joints) served as 
non-operated controls. 
 Ex vivo impact stress correlated well with force to the 1/3 power as predicted by Hertzian 
contact mechanics. Joint fluid and histology results were consistent with the development of 
early PTOA in all injured joints. The severity of focal osteochondral injury correlated to the 
magnitude of impact delivered (r2 = 0.80, p = 0.016).  
 These studies establish mechanical thresholds for tissue damage and connect mechanical 
inputs to in vivo development of early PTOA-like lesions. Development of an equine talocrural 
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cartilage impact model, which creates cartilage injury similar to that expected to initiate PTOA 
in the human ankle, will allow investigation of very early events in PTOA at the cellular and 
microstructural level ex vivo and in vivo. This model will also allow preclinical testing of 
preventative strategies (e.g. exercise modification) and potential disease modifying therapies to 
minimize progression of PTOA. 
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Introduction  
 Osteoarthritis (OA) that develops secondary to a wide variety of joint injury is often 
grouped into the sub-type of post-traumatic osteoarthritis (PTOA). Common precipitating 
injuries include high-speed impact trauma to the articular surface, intraarticular fractures, and 
joint-destabilizing soft-tissue tears. Although the end-stage pathophysiology of PTOA may be 
similar, there is strong evidence to suggest that the early biological and mechanical events that 
initiate and perpetuate disease are distinct between different joints, injury types, and patient 
populations, as discussed in Chapter 2. The ankle is the most commonly injured joint, and up to 
90% of ankle OA occurs secondary to joint trauma.1-5 This is in stark contrast to knee and hip 
OA, where just 2-10% is attributed to a previous injury.1,2,6  
 The most common injury precipitating end-stage ankle OA is a severe ankle sprain,7 
when rapid ankle inversion causes the distal tibia to impact the medial aspect of the talar dome, 
often resulting in an osteochondral lesion.8,9 Ligamentous injuries commonly accompany severe 
ankle sprains and may result in joint instability, however evidence suggests that the magnitude of 
the initial cartilage trauma is the most important factor in development of ankle PTOA.  
 Most PTOA models utilize smaller animal species, and involve creating an osteochondral 
fragment, intraarticular fracture, or joint destabilization in the knee (stifle) joint. As discussed in 
Chapter 2, these are useful models, however there are currently no animal models that simulate 
PTOA of the ankle joint arising from traumatic overloading of the articular surface of the talus, 
as would be expected during a severe sprain. Therefore, our goal was to develop a large animal 
ankle model of impact-induced PTOA. Specifically, our objective was to use a minimally 
invasive surgical approach to deliver a tunable injury to the articular surface of the equine talus, 
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which progresses to a cartilage lesion of predictable severity and depth, in order to simulate early 
OA lesions seen in humans.10  
 Specific aims of the ex vivo validation portion of the study were to: 1) determine how 
measurable mechanical inputs relate to the magnitude of acute cartilage injury in this model 
system, and 2) establish force-stress relationship in order to predict stresses from load cell data 
obtained during in vivo impact. The aims of the in vivo portion of the study were to: 1) develop a 
minimally invasive approach to apply a defined mechanical injury to the equine talus using a 
hand-held spring-loaded impacting device, and 2) study early disease development in vivo at 6 
and 12 weeks post-operatively. 
 
Methods  
 
Ex vivo validation studies 
 Impactor modification. A spring-loaded impacting device, originally described by 
Alexander, et al.,11 and recently modified by Bonnevie, et al.,12 was further adapted to allow ex 
vivo impact of osteochondral (OC) preparations of the equine talus (Figure 3.1). An adjustable 
vice grip, capable of rotation on 3 axes, was installed below the impactor armature (Figure 
S3.1a). One of 2 hemispherical impacting tips, differing in diameter and radius of curvature, 
were mounted on the end of the spring-driven missile contained within the device. A load cell 
(PCBPiezotronics, Depew, NY) mounted in-line between the missile and the impacting tip was 
used to measure impact force. A linear variable displacement transducer (LVDT; RDP 
Electronics, Pottstown, PA) was attached to the impacting tip to measure displacement (Figure 
3.1.)  
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Figure 3.1. Ex vivo model development.  A) The spring-loaded impacting device was instrumented with 
an internal load cell to measure force and a linear variable displacement transducer (LVDT) to measure 
displacement. One of 2 impact tips (s and L; inset). Modified from Bonnevie, et al., 2015. Reused with 
permission from SAGE Publications. B) The impact voltage signal from the load cell was converted to 
stress, using the contact area of each impact measured on pressure sensitive paper.  C) Multiple impacts 
were applied to each equine talus in areas (*; zones 4 and 6) corresponding to the highest incidence of 
osteochondral lesions in humans. 
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 Tissue collection and handling. OC blocks comprising the medial and lateral trochlea of 
the right and left talus were harvested from 6 normal adult horses (ages 2-11 years) immediately 
following euthanasia, and incubated in phenol red-free MEM supplemented with HEPES 
(25 mM), penicillin (100 IU/ml), and streptomycin (100 µg/ml). OC blocks were mounted in the 
adjustable vice grip, and positioned with the articular surface perpendicular to the direction of 
impact (Figure S3.1a). While mounted, samples were kept moist by continuous lavage with 
phosphate buffered saline (PBS).  
 Impact and mechanical analysis. The articular surface of the talus was impacted in 
regions corresponding to the highest incidence of naturally occurring OC lesions in humans,8 as 
previously described.11,12 The purpose of this portion of the study was to determine the 
relationship between force and stress, to obviate the technical challenges of measuring impact 
surface area during in vivo experiments. Briefly, a total of 180 impacts (6-10 impacts per OC 
block, spaced approximately 0.5 cm apart) of varying magnitudes were applied to the mid-
medial and lateral trochlea of the talus using one of 2 curved impacting tips (Figure 3.1). Load 
cell and LVDT output (voltage) were acquired simultaneously at 50kHz with a custom 
LabVIEW program (NI, Austin TX). Cartilage thickness (t) was measured by modified needle 
probe technique13 on a mechanical testing frame (EnduraTEC ELF3200, EnduraTec, 
Minnetonka, MN) and validated by manually by cutting and photographing OC blocks in cross-
section adjacent to impacts, then measuring thickness on digital images using ImageJ software 
(Mac OS X version 10.2, Wayen Rasband, U.S. National Institutes of Health, Bethesda, MD, 
USA; Figure S3.1c). LVDT output was converted to displacement (d), then strain was calculated 
as (d)/(cartilage thickness). Load cell data (voltage) was converted to force (F), then average 
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peak stress was calculated as (max F)/(contact area of indenter) recorded by pressure sensitive 
film (FujiFilm Prescale, Tokyo, Japan) and measured using ImageJ (Figure S3.1b).  
 Multiphoton imaging and histology. Impacted OC blocks were incubated in media for 
approximately 2 hours, then full-thickness cartilage sections containing the impact or control site 
were cut off the bone and placed in 1 µM sodium fluorescein (AK-FLOUR 25%, Akorn, Inc., 
Lake Forest, IL) in PBS for 15 minutes to stain dead cells. Samples were then imaged on a 
multiphoton microscope using a Ti:sapphire laser at 780 nm excitation, as previously 
described.14 Images were acquired at the articular surface in the transverse plane (i.e. parallel to 
the articular surface). Dead cells were quantified using a custom ImageJ macro and extracellular 
matrix (ECM) microcracks were assessed qualitatively (Figure S3.1d). Impacted and control 
cartilage samples were fixed in 4% paraformaldehyde, then sectioned and stained with 
hematoxylin and eosin (H&E) and safranin O/fast green to assess structural damage, acute 
cellular necrosis and proteoglycan content. The purpose of this portion of the study was to 
determine the range of impact magnitudes to be tested in vivo; the goal was to create partial-
thickness cartilage pathology, involving approximately 50-75% of the cartilage depth, with cell 
death and fissures extending into the deep zone, but not involving the calcified cartilage layer.   
 
In vivo model development 
 Animal subjects. To determine the relationship between impact magnitude and cartilage 
degradation in vivo, two healthy, young adult (3 year old) female horses (n = 4 joints) were 
operated. Prior to surgery, all TC joints were deemed free of pre-existing OA by 2 board certified 
equine surgeons on the basis of normal physical examination, gait evaluation, and synovial fluid 
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analysis. Two joints (1 horse) served as un-operated controls. All animal experiments were 
approved by Cornell University’s Institutional Animal Care and Use Committee. 
 Surgical technique. The arthroscope was inserted and the joint was inspected for pre-
existing pathology. An instrument portal was created half way between the arthroscope portal 
and the lateral malleolus. The impactor tip was inserted into the joint and positioned 
perpendicular to the articular surface of the axial aspect of the medial trochlea of the talus. The 
impactor was held in contact with the articular surface, and the impactor trigger was depressed 
(Figure S3.2). The joint was then flexed several degrees, the spring tension was adjusted to set 
the impact magnitude, and the impactor spring was compressed. A second impact was delivered 
~5 mm distal to the first. This was repeated a third time, so that a total of 3 impact were created 
along the mid-distal medial trochlea of the talus (Figure 3.2) load cell data were recorded and 
analyzed, as described above.          
 Postoperative monitoring and synovial fluid analysis. Postoperatively, horses were 
examined daily for clinical evidence of pain (lameness). Joint effusion was scored on a 4-point 
scale (Table S3.1). Synovial fluid was obtained weekly, starting 1 week postoperatively for 4 
weeks, then at 6, 8, and 12 weeks postoperatively. Synovial fluid cytology was evaluated by a 
board certified veterinary clinical pathologist, and total protein, nucleated cell count, and 
differential cell counts were measured. Synovial fluid characteristics (viscosity, color, turbidity) 
reported by the clinical pathologist were combined into a single joint inflammation score (Table 
S3.1). Additional aliquots of synovial fluid were stored at -80°C until further analysis, when 
synovial fluid biomarkers of early OA (PGE2 and TNFα) were measured on ELISA.15-17 
Cytokine concentration was quantified using commercial ELISA kits (PGE2 ELISA kit, Enzo 
Life Sciences catalog # ADI-900-001 and Equine TNF alpha ELISA Kit, Thermo Scientific  
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Figure 3.2. Hand-held impactor creates cartilage lesions in vivo.  A) Intraoperative arthroscopic view 
of 3 impacts (arrows) of varying magnitude created on the medial trochlea of the left talus in horse 1.   
The impacting tip (star) is positioned through a standard arthroscopic portal within the joint. B) Post 
mortem dissection of the same joint; india ink has been applied to the articular surface to mark impact 
sites (arrow heads).!
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ESS0017). The assays were completed using undiluted synovial fluid according to 
manufacturers' directions, and the 96-well plate was read on a spectrophotometric microplate 
reader (Tecan Safire; Männedorf, Switzerland). 
 
Tissue collection, gross pathology and histopathology 
 Horses were sacrificed 6 or 12 weeks postoperatively to examine acute stages of 
PTOA.17,18 India ink was applied to the articular surface of the medial talus to identify areas of 
cartilage cracking and fibrillation. Suspect areas of impact (well-circumscribed, circular areas of 
intense India ink uptake on the axial aspect of the mid-distal aspect of the medial trochlea of the 
talus) were identified, and this information was cross-referenced with arthroscopic videos 
obtained during surgery to confirm the location of individual impact sites (Figure 3.2). OC 
blocks containing each of the three impact sites, the opposing articular surface (distal 
intermediate ridge of the tibia; DIRT) and the un-injured lateral trochlear ridge of the talus 
(LTR) were harvested, fixed in 4% paraformaldehyde, and decalcified using 20% sodium citrate 
and 44% formic acid. OC sections were stained with H&E and Safranin O/Fast green. Histology 
was scored by two independent observers (MLD, LD) blinded to treatment (i.e. injury status and 
magnitude), based on a 24-point modified OARSI scoring system (Table S3.2) and using the 6-
point OARSI grading system.19 Synovial membrane was harvested, processed and stained with 
H&E and consensus scored (Table S3.3) by one experienced observer (MLD) and a board-
certified clinical pathologist (ADM) blinded to treatment.  
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Statistical analysis 
 The relationship between impact force and impact stress was determined based on 
Hertz’s contact theory,20 where stress is related to force1/3. Linear regression was conducted 
between these 2 variables. The relationship between OARSI score at 12 weeks post-impact and 
peak impact stress was determined using linear regression. 
 
Results 
 
Ex vivo  
 Based on Hertzian contact mechanics, the relationship between impact stress and impact 
force was determined. As expected, impact stresses for cartilage under impact from a spherical 
tip correlated well with impact force1/3 as predicted by Hertzian contact mechanics20,21 (Figure 
3.3). For both the small and large radius impacting tips, the correlations provided R2 = 0.71 and 
R2 = 0.50, respectively. The increased slope between the small and large radius tips is an effect 
of contact area, where smaller contact areas provide larger stresses at the same force level.  
 
In vivo  
 Clinical observations and synovial fluid analysis. No major complications were 
experienced intra- or post-operatively. Mild to moderate synovial effusion was present in all 
impacted joints and decreased gradually throughout the study period, with no observable 
lameness at any time point. Based on synovial fluid analysis and clinical observation, joint 
inflammation resolved within 2 weeks of impact, but joint inflammation scores did not return to 
baseline in any experimental joint (Figure 3.4), indicating low-grade pathology   
 
! 76!
 
 
 
 
 
 
 
 
 
Figure 3.3. Relationship between impact force and stress for the equine talus. 
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Figure 3.4. Cartilage impact causes joint inflammation.  A) Joint inflammation score, a combined 
measure of synovial fluid changes and clinical joint effusion remains elevated throughout the 12-week 
study.  B) PGE-2 concentrations were increased one week following impact, and returned to baseline 
levels within 4 weeks. Error bars = ±s.d. C) Synovial histopathology was scored for inflammation, 
vascularity and subintimal edema, and revealed mild to moderate synovitis at 6 weeks (joints 3 and 4) and 
12 weeks (joints 1 and 2) post-impact. Control data represent the average of 2 joints. D)  Representative 
20x images of synovial sections stained with hematoxylin and eosin from control and injured joints.!
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throughout the course of the study. PGE-2 increased an average of 2.5 fold (range 1.5-4x) 1 
week postoperatively, and returned to baseline by 4 weeks in 3 of the 4 joints (Figure 3.4). 
 Synovial membrane histopathology. Histopathologic examination of the synovial 
membrane from injured joints indicated mild to moderate inflammation, with or without 
subintimal edema and/or increased vascularity (Figure 3.4). None of the synovium sections 
showed evidence of subintimal fibrosis or intimal hyperplasia. These changes indicate mild to 
moderate synovitis at 6 and 12 weeks post-injury, in agreement with synovial fluid analysis 
results. 
 Gross and histopathologic osteochondral lesions. At necropsy, all impact sites were 
grossly identified with the application of India ink. Typically, impacts were easily 
distinguishable as a cluster of radiating cracks, and in all cases correlated well to images 
obtained at arthroscopy (Figure 3.2). All OC sections from areas of impact showed 
histopathological evidence of early OA-type lesions (Figure 3.5). Changes ranged from mild to 
severe erosions, cracking/fissuring, hypocellularity, chondrocyte necrosis and clonal expansion 
of chondrocytes with an average modified OARSI score of 14.8 (s.d. 4.0) out of 24 and a mean 
OARSI Grade19 of 3.5 (s.d. 1.1) out of 6 (Figure 3.5). At 3 months following injury, OARSI 
grade for individual impacts correlated with impact magnitude (r = 0.8953, p = 0.016; Figure 
3.5).  
 
Discussion 
 The goal of this work was to develop an in vivo large animal model of impact-induced 
osteochondral injury to study early ankle PTOA. At 6 and 12 weeks after injury, impact sites 
show histopathologic evidence of moderate to severe OA lesions, and the severity of damage  
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Figure 3.5. Impact causes early OA-like osteochondral lesions and cartilage damage is correlated 
with impact stress. A) Average OARSI score by experimental joint (1-4) revealed moderate to severe 
OA at the impact sites (grey) and mild changes in the two non-impacted areas within the experimental 
joints (black). Error bars = ±s.d.  B) OARSI score at 12 weeks correlated with peak impact stress. C) 
Representative 10x images of osteochondral sections stained with safranin O/fast green (SOFG) and 
hematoxylin and eosin (H&E) of OARSI grades 0, 3, 4 and 5.  Note the persistence of India ink (black) 
applied at necropsy, marking impacts. Bars = 150µm. 
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was correlated with impact magnitude. The range of impact magnitudes tested in vivo were 
carefully selected based on extensive ex vivo model development, allowing the number of 
animals used for the in vivo portion of the study to be minimized. The impact-induced 
histopathologic lesions are similar to those observed in clinical cases of posttraumatic 
osteoarthritis, with lesions ranging in severity from OARSI grade 3-5. In addition to producing 
focal osteochondral lesions typical of early OA, cartilage injury alone was sufficient to cause 
joint-wide pathology, evidenced by persistent joint inflammation scores throughout the study 
period, and synovitis on histopathology. This is a unique feature of our model, in that a 
minimally invasive surgical approach allowed us to apply articular trauma without damaging 
supporting ligamentous structures and other surrounding soft tissues.   
 The horse was selected as the model species of choice for several reasons. First, the horse 
is the largest available model species with an average weight of 400-500 kg, which provides 
stringent loading conditions within the joint. Similar to the human ankle, the equine TC joint has 
a higher GAG content and is stiffer than that of the knee.22 Equine cartilage is similar in 
thickness to humans which allows creation of partial-thickness lesions, which is difficult to 
achieve in similar models using small animal species.23 In a recent review of preclinical cartilage 
defect models, the horse was the only species to be placed in group 3 with humans in cluster 
analysis, indicating that the horse is the only animal model in which defect dimensions relevant 
to human clinical practice can be produced.24 Furthermore, the large size of the equine talocrural 
joint allows the arthroscope and impactor to be positioned within the joint. Arthroscopic 
visualization ensures appropriate anatomic placement of the impactor tip perpendicular to the 
articular surface during cartilage injury.  
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 The opportunity for second-look arthroscopy is an important feature of this model. As 
discussed in Chapter 2, clinical evidence in human patients with ankle injuries suggests that 
arthroscopic examination of the ankle joint is particularly important in identifying early evidence 
of PTOA. After severe ankle sprain, early chondral lesions that are difficult or impossible to 
diagnose on MRI, are often identified on arthroscopy.25-28    
 Limitations of this study include the small number of animals used for the in vivo portion 
of the study and that non-operated controls were used instead of sham-operated controls. Despite 
low animal numbers, when impacts were analyzed individually, peak impact stress correlated 
well with the severity of cartilage lesions at 12 weeks. This indicates that the severity of cartilage 
injury in this model system can be tuned by adjusting both impactor spring tension as well as 
impact tip geometry. While the scope of this study did not include advanced imaging, MRI is a 
well validated diagnostic modality to assess the equine TC joint, and future studies will employ 
MRI for non-invasive longitudinal evaluations of cartilage and subchondral bone changes.29-32 
 Development of an equine talocrural cartilage impact model, which creates cartilage 
injury similar to that expected to cause PTOA in the human ankle, will allow investigation of the 
very early events in PTOA pathogenesis at the macroscopic and cellular/microstructural level, as 
well as longitudinal studies of disease progression. This model will allow preclinical testing of 
preventative strategies such as exercise modification, targeted drug therapies, regenerative 
medicine modalities, etc. in a clinically relevant large animal species. 
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Supplement 3.1 - Detailed Methods 
 
Development of the in vivo surgical approach  
 Three adult horses, euthanized for reasons other than this study were used to develop the 
in vivo surgical technique. Briefly, two intact left talocrural joints were harvested by transverse 
cuts through the distal tibia and proximal metatarsus. Large gauge Steinmann pins were driven 
down the shafts of the long bones to pin one joint in maximum flexion and the other in maximum 
extension. Skin and soft tissues were removed and margins of maximum articulation of the tibia 
were marked on the talar joint surface. The pins were removed and the joints were disarticulated. 
Digital images were obtained and used to lay out the 9-zone grid system, as described for the 
human talus by Raikin, et al. (Figure 3.1c) Two cadaveric limbs were used to develop the 
arthroscopic approach described in Surgical technique.    
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Figure S3.1. Ex vivo cartilage impact.  A) Impactor mounted to armature, with talar OC block held in a 
vice grip, which rotates in 3-axis to allowing the impacting tip to be positioned perpendicular to articular 
surface. B) Impact footprints were recorded using pressure sensitive film and surface area was measured 
using the ImageJ software masking function (inset). C) Cartilage thickness was measured on cut section 
adjacent to impact sites using ImageJ software. D) Live multiphoton images (10x) of control and 
impacted cartilage. Cartilage matrix cracks (arrows) and dead cells (circled) are present after impact.  
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Figure S3.2. Arthroscopy video of talus impact.  Scan the QR code with a QR code reading app on 
your smart phone or visit: https://vimeo.com/179513366 and enter the password “impact” to view the 
video. 
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Table S3.1. Rubric for joint inflammation score 
 
Analysis              Parameter Score Qualifications 
Synovial Fluid Color/clarity/viscosity 0 Normal 
1 Abnormal   
Total Protein 0 <2.5 
1 2.5-4   
2 >4 
Nucleated cell count 0 <1000 
1 1000-9000   
2 >9000 
% Neutrophils on 
differential cell count 
0 0-15% 
1 15-65% 
2 >65% 
Cellular morphology 0 Normal 
1 Abnormal 
Clinical 
Examination 
 
Joint effusion 0 None (Normal) 
1 Mild  
2 Moderate 
3 Severe 
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Table S3.2. Modified OARSI osteochondral histology scoring for in vivo impact model 
 
Analysis Score Qualifications 
Cartilage Structure  
(Fibrillation/fissuring of the 
articular cartilage surface)          
0 None (Normal) 
1 Restricted to surface/superficial zone  
2 Fissures/clefts extends into middle zone 
3 Extends to level of deep zone 
4 Extends into the deep zone 
5 Full thickness loss (to calcified cartilage) 
Tidemark/subchondral bone 
remodeling 
 
0 None (Normal) 
1 Duplication of tidemark, advancement of 
SC bone into calcified cartilage, 
scalloped margins 
2 Advancement of SC bone through 
tidemark(s) 
3 Complete disruption/disorganization of 
tidemark, SC bone 
Chondrocyte necrosis  
(Necrotic cells near the 
articular surface per 20X 
objective) 
0 Normal 
1 1 necrotic cell 
2 1-2 necrotic cells 
3 2-3 necrotic cells 
4 3-4 necrotic cells 
Focal cell loss  
(Area of acellularity per 20x 
field) 
0 Normal 
1 10-20% 
2 20-30% 
3 40-50% 
4 >50% 
Cluster (complex chondrone) 
formation 
0 None 
1 2 chondrocytes 
2 2-3 chondrocytes 
3 3-4 chondrocytes 
4 >4 chondrocytes 
Loss of GAG staining        
(on SOFG) 
 
0 Normal 
1 <25% loss 
2 25-50%  
3 50-75%   
4 >75%  
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Table S3.3. Synovial membrane histopathology scoring for in vivo impact model 
 
Analysis Score  Qualifications 
Inflammatory cell 
infiltration  
 
0 None 
1 Mild presence in 25% 
2 Moderate presence in 25-50% 
3 Marked presence in >50% 
Vascularity 
(Number of vessels) 
0 Normal 
1 Mild increase in focal areas 
2 Moderate increase up to 50% 
3 Marked increase in >50% 
Intimal hyperplasia          0 None  
1 Villi with 2-4 rows intimal cells              
2 Villi with 4-5 row 
3 Villi with >5 rows 
Subintimal edema  0 None 
1 Mild edema in 25% 
2 Moderate edema in 25-50%   
3 Marked edema in >50% 
Subintimal fibrosis   0 Normal 
1 Mild increase in 25% 
2 Moderate increase in 25-50% 
3 Marked increase in >50% 
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Abstract 
 
Mitochondrial (MT) dysfunction is known to occur in chondrocytes isolated from end-stage 
osteoarthritis (OA) patients, but the role of MT dysfunction in the initiation and early 
pathogenesis of post-traumatic OA (PTOA) remains unclear.  The objective of this study was to 
investigate chondrocyte MT function immediately following mechanical injury in cartilage, and 
to determine if the response to injury differed between a weight bearing region (medial femoral 
condyle; MFC) and a non-weight bearing region (distal patellofemoral groove; PFG) of the same 
joint. Cartilage was harvested from the MFC and PFG of 10 neonatal bovids, and subjected to 
injurious compression at varying magnitudes (5-17MPa, 5-34GPa/sec) using a rapid single-
impact model. Chondrocyte MT respiratory function, MT membrane polarity, chondrocyte 
viability and cell membrane damage were assessed in situ. Cartilage impact resulted MT 
depolarization and impaired MT respiratory function within 2 hours of injury. Cartilage from a 
non-weight bearing region of the joint (PFG) was more sensitive to impact-induced MT 
dysfunction and chondrocyte death than cartilage from a weight-bearing surface (MFC). Our 
findings suggest that MT dysfunction is an acute response of chondrocytes to cartilage injury, 
and that MT may play a key mechanobiological role in the initiation and early pathogenesis of 
PTOA. Clinical significance: Direct therapeutic targeting of MT function in the early post-injury 
time frame may provide a strategy to block perpetuation of tissue damage and prevent the 
development of PTOA.  
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Introduction 
  
 Despite decades of evidence establishing a link between mechanical injury to cartilage 
and post-traumatic osteoarthritis (PTOA),1,2 no effective therapies exist to prevent or slow 
progression of the disease.3 A sizeable body of research has focused on the molecular, cellular, 
and structural changes occurring in the days to weeks following cartilage injury. However, 
mounting evidence suggests that interventions must target the earliest pathologic events in order 
to modify the disease course.4,5 Therefore, an improved understanding of the acute (within hours) 
events after cartilage injury is necessary to develop novel preventative therapies.  
 Mitochondria (MT) are subcellular organelles that drive tissue development, repair, and 
aging.6 In addition to their role in cellular ATP production by oxidative phosphorylation, MT act 
as intracellular mechanotransducers via strain-mediated release of reactive oxygen species 
(ROS), which function in normal cell signaling.7,8 When MT dysfunction, cellular energy 
production declines and ROS are produced in excess, leading to degradation of lipid membranes, 
accumulation of DNA damage, initiation of catabolic signaling cascades, and cell death.9 
Apoptosis is triggered when cytochrome C dissociates from the inner MT membrane and 
activates the caspase cascade in the cytosol.10  
 Bioenergetic failure, cumulative oxidative stress, and MT-mediated apoptosis are 
implicated in the pathogenesis of many complex degenerative diseases,11 and substantial 
evidence supports a role for MT dysfunction in the chronic stages of osteoarthritis (OA).12-14 In 
chondrocytes isolated from patients with end-stage OA, MT dysfunction is associated with later-
stage pathologic events including upregulation of matrix metalloproteinase-1, -3 and -13, 
decreased synthesis of collagen and proteoglycans, and pathologic calcification of cartilage.15,16 
Additionally, MT dysfunction and oxidative stress were recently linked to chronic overloading of 
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chondrocytes.17 Several studies provide indirect evidence that MT play a central 
mechanobiological role in impact-induced chondrocyte death. For example, MT-derived ROS 
contribute to chondrocyte death after cartilage injury,18 and antioxidants prevent impact-induced 
cell death.19,20 Furthermore, inhibition of calcium signaling and activation of the caspase cascade 
after cartilage injury can prevent impact-induced chondrocyte death.21 These findings suggest a 
causal link between MT-dysfunction and PTOA pathogenesis, however, a significant knowledge 
gap remains in identifying the relationship between mechanical injury, in situ chondrocyte MT 
respiratory function, and cell death immediately after impact injury. 
 The objective of this study was to investigate chondrocyte MT function in situ 
immediately following cartilage impact injury using a real-time microscale respirometry assay 
modified for explanted cartilage. Our hypothesis was that MT dysfunction is an acute response 
of chondrocytes to mechanical injury. Furthermore, we hypothesized that a joint surface adapted 
to withstand predominantly compressive loads during weight-bearing (the MFC) would be less 
sensitive to impact-induced cell death and MT dysfunction than a non-weight-bearing region 
within the same joint.  
 
Methods 
 
Cartilage Harvest and Mechanical Injury 
 Healthy bovids (n = 10; 1-3 days of age) were obtained from a livestock auction and 
humanely euthanized in accordance with AVMA guidelines.22 Within 12 hours of sacrifice, full 
thickness cartilage explants were harvested from both the left and right knee joints, using an 
8mm biopsy punch (Figure 4.1a). Explants were rinsed in phosphate-buffered saline (PBS), 
trimmed to a uniform thickness of 3mm from the articular surface using a custom jig, and placed 
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in cartilage explant media (phenol-free DMEM containing FBS 10%, HEPES 0.025ml/ml, 
penicillin 100U/mL and streptomycin 100U/mL). All animal experiments were approved by 
Cornell University’s Institutional Animal Care and Use Committee.  
 Explants were subjected to a single, rapid impact injury using a validated model, as 
previously described, or served as un-injured controls.23 Briefly, explants were positioned in a 
well containing media under the plane-ended tip of a spring-loaded impacting device.23,24 Impact 
magnitude was adjusted by setting the deflection of the impactor’s internal spring. During 
impact, force was measured at 50 kHz by an in-line load cell (PCB Piezotronics, Depew, NY) 
and displacement was measured by a linear variable differential transducer (LVDT; RDP 
Electronics, Pottstown PA) attached to the impactor tip. Voltages from the load cell and LVDT 
were recorded simultaneously with a custom LabVIEW program (NI, Austin TX) and 
mechanical parameters for each impact were calculated as previously described.23  
 
Characterization of In Situ Chondrocyte Mitochondrial Respiratory Function Immediately 
Following Cartilage Injury 
The goal of the first set of experiments was to determine the effect of acute mechanical 
injury on chondrocyte mitochondrial function. Microrespirometry has previously been used to 
investigate respiratory function of cultured chondrocytes,17,25 but has not been applied to 
chondrocytes in situ. Studying chondrocytes within their native extracellular matrix minimizes 
alterations in the mechanobiological environment and shortens the time frame between injury 
and observation. Therefore, based on previously described modifications of this technique for  
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Figure 4.1.  Experimental design and methods. A) Cartilage explants were harvested from the medial 
femoral condyle (MFC) for the first set of experiments, and from 2 sites for the second set of 
experiments; the MFC and the distal patellofemoral groove (PFG). One explant from each region was 
impacted at a higher impact magnitude, one was impacted at a lower magnitude, and one served as an un-
impacted control. Explants were then divided for use in several assays; chondrocyte viability was 
quantified using live/dead staining, mitochondrial (MT) membrane polarity was determined as red to 
green fluorescent intensity (R:G) ratio on confocal imaging and MT respiratory function was assessed via 
microrespirometry. Cell membrane damage was assessed by measuring lactate dehydrogenase (LDH) 
activity in cartilage conditioned media. B) MT respiratory function was quantified by measuring oxygen 
consumption rate (OCR) over time. After basal OCR was determined, a MT stress test was performed by 
sequential addition of 1) oligomycin, an ATP synthase inhibitor 2) FCCP, a proton circuit uncoupler 3) 
rotenone (Rot) and antimycin A (Ant A), inhibitors of MT complexes I and III.  Parameters of respiratory 
control were calculated as depicted by the shaded areas under the curve.  
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use in whole tissues26,27 and after assay optimization (Supplement 4.1, Detailed Methods), real-
time microscale respirometry was used to measure chondrocyte MT respiratory function in 
explanted cartilage, as follows. Explants (n = 65 total) from the medial femoral condyle (MFC) 
were harvested and impacted over a broad range of injury magnitudes (M1-M4; 5-17MPa, 5-
34GPa/sec; Table 1), as described above. This range was selected based on preliminary trials 
(160 explants, 8 trials) and previous work23 to determine the stress and stress rate thresholds 
associated with cell death and extracellular matrix damage in this system. The goal was to apply 
a range of injury magnitudes, from minimal cell death (M1) to cell death without surface 
cracking (M2) to subcritial damage (i.e. impacts that produced surface fissuring but not full 
thickness defects; M3 and M4, Table 4.1).   
 Following impact, two cartilage disks (3mm diameter x 500um thickness from the 
articular surface) were prepared (Supplement 4.1) and immediately loaded into a randomly 
assigned well of a 24-well tissue capture microplate (Seahorse Biosciences, Billerica, MA) 
containing assay media (bicarbonate-free DMEM supplemented with 2.5mM glucose, 2mM L-
glutamine, 2 mM pyruvate, and 1% FBS). Following a calibration cycle, glycolysis and oxidative 
phosphorylation were quantified every 8 minutes for a minimum of 225 minutes by measuring 
extracellular acidification (ECAR) and oxygen consumption rates (OCR) within each well, 
respectively using an XF24 Extracellular Flux Analyzer (Seahorse Biosciences). After basal 
respiration was measured for at least 40 minutes, a MT stress test was performed according to 
standard protocols, as previously described.9,25,28 Briefly, OCR was measured in response to the 
automated sequential addition of 1) oligomycin (1.5 uM), an ATP synthase inhibitor 2) carbonyl 
cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP; 1.0 uM), a proton circuit uncoupler 3) a  
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 Table 4.1. Mechanical parameters of impact by experimental group!
!
  Impact Magnitude 
Experimental 
Group 
Mean Peak Stress; 
MPa (+/- s.d.) 
Mean Peak Stress Rate; 
GPa/sec (+/- s.d.) 
Control n/a n/a 
M1 5.6  (0.4) 6.7  (1.3) 
M2 7.5  (0.4) 9.3  (1.5) 
M3 14.1  (0.7) 28.1  (1.8) 
M4 16.2  (0.7) 32.0  (1.6) 
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combination of rotenone (0.5 uM) + antimycin A (1.0 uM), inhibitors of MT complexes I and III, 
respectively (Seahorse Biosciences).  
 The remainder of each explant was used to determine chondrocyte density and viability, 
as described below, in order to normalize respirometry data to viable cell number on an 
individual explant basis (Supplement 4.1). Data were normalized to viable cell number by 
dividing OCRs measured in each well containing a single cartilage plug, by the number of viable 
cells in that well. MT functional indices were calculated as previously described9,25 and visually 
represented in Figure 1b, using OCR values as follows: basal OCR (bOCR) = initial OCR – 
nonMT respiration (NMR); maximal (uncoupled) respiration (mOCR) = FCCP stimulated OCR 
– NMR; spare respiratory capacity (SCR) = (uncoupled respiration – NMR) – (bOCR – NMR); 
Proton leak = (oOCR– NMR). 
 
Chondrocyte Viability and Cell Membrane Damage Assays 
 In order to determine cell density and quantify chondrocyte viability, cartilage was placed 
in PBS containing calcein AM (2uM) and ethidium homodimer (1uM) for 30 minutes at 37°C in 
the dark, to stain live and dead cells, respectively. Explants were then rinsed in PBS and imaged 
on a Leika SP5 confocal microscope. Digital z-stacked images were acquired in two channel 
sequential scans (488/498-544 and 514/563-663 nm excitation/emission, respectively) using a 
modified 3D scanning protocol consisting of 10 z-stacked 512x512 pixel (387.5µm x 387.5µm) 
images spaced 10um apart in the z plane at 20x magnification. The number of live, dead, and 
total cells in each image was quantified using a custom ImageJ macro (Supplement 4.1). The 
explant volume and chondrocyte density were calculated for each explant and used to normalize 
respirometry data to viable cell number (Supplement 4.1).   
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  As a measure of cell membrane damage, lactate dehydrogenase (LDH) activity was 
assayed in cartilage-conditioned media from each well of the XF assay plate, according to 
manufacturer’s instructions (Sigma-Aldrich, St. Louis, MO). Briefly, equal volumes of cartilage-
conditioned media and kit reagent were added to a 96-well plate and absorbance was measured at 
450nm in 5-minute intervals by a spectrophotometric microplate reader (Tecan Safire; 
Männedorf, Switzerland). To established a post-impact LDH release time-course and validate the 
use of media obtained from the XF assay plates following microrespirometry assays, cartilage 
explants (n = 16) were impacted at the magnitudes described above (M1-M4: Table 4.1), and 
incubated for 24 hours in cartilage explant media. LDH assay was performed on cartilage-
conditioned media at 1, 5, 7 and 24 hours after impact.  
 
Comparison of chondrocyte response to injury between two locations within the same joint 
 The goal of the second set of experiments was to compare MT response to injury between 
a weight bearing and non-weight bearing surface within the same joint. Explants were harvested 
from the medial femoral condyle (MFC) and distal patellofemoral groove (PFG), as described 
above (n = 40 total). The MFC is the main weight-bearing surface of the knee, while the distal 
PFG is a non-weight bearing articular surface. Three explants were harvested from two locations 
within each joint. One explant from each area was subjected to one of 3 impact treatments; lower 
magnitude (M1; 5.6 ±0.4 MPa mean peak stress, 6.7 ±1.3 GPa/sec mean peak stress rate), higher 
magnitude impact (M2; 7.5 ±0.4 MPa, 9.3 ±1.5 GPa/sec) or non-impacted control. 
Microrespirometry was performed (n = 8/group) and data was normalized as described above. 
Impact magnitudes (M1 and M2) were chosen based on preliminary data, which revealed that 
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impact above ~8MPa peak stress (~11GPa/sec peak stress rate) in the PFG resulted in extensive 
cell death, preventing comparisons to the MFC (Figure S4.1).  
 
Mitochondrial Membrane Polarity Assay   
 The functional integrity of the inner MT membrane was assessed in situ using confocal 
imaging of fluorescent MT probes. Following impact and sectioning, samples (n = 40) were 
placed in PBS containing tetramethylrhodamine methyl ester perchlorate (TMRM;10nM, 
Molecular Probes), MitoTracker Green (MTrG; 200nM, Molecular Probes, Eugene, OR), and 
Hoechst 33342 (1ug/ml, Molecular Probes) for 40 minutes and protected from light. TMRM is a 
polarity-sensitive MT probe, and red fluorescence indicates active transport of the dye across a 
polarized (functional) MT membrane. MTrG is a polarity-insensitive MT probe, which stains all 
MT regardless of MT membrane potential. Hoechst acts as a nuclear counterstain, and 
preferentially stains cells with compromised plasma membranes. After staining, explants were 
rinsed in PBS and imaged on a Leica SP5 confocal microscope. Images were acquired and 
analyzed as described above (for live/dead staining), with the exception that 1024x1024 pixel 
(775µm x775µm) images were acquired in three channel sequential scans (405/411-497, 
488/498-544 and 561/569-611 nm excitation/emission, respectively) spaced 5um in the z-plane 
at 20x magnification and red:green florescent intensity (R:G) ratios for each image were 
determined using a custom ImageJ macro (Supplement 4.1). Macros for each imaging channel 
were optimized and image-wide analysis of R:G ratio was validated by manual ROI selection of 
individual cells at higher (40x) magnification for control and impacted explants. 
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Statistical Analysis 
 The response variables bOCR and mOCR were analyzed using a linear mixed effects 
model with fixed effects of treatment group and site (MFC or PFG) and random effect of trial 
(animal) and limb (left or right). The unit of study was a cartilage explant. The relationship 
between impact magnitude (stress and stress rate) and chondrocyte death was analyzed using a 
linear regression model. A one-way ANOVA was used to compare response variables between 
treatment groups.  Post-hoc pairwise comparisons between treatment groups were performed 
using Tukey’s HSD method to control for multiple comparisons. Residual analyses were 
performed on log-transformed data to ensure the assumptions of normality and homogeneous 
variance were met. Differences were considered statistically significant when p < 0.05. All 
statistical analyses were performed using JMP Pro Version 11.0 (SAS Inc.) software. 
 
Results 
 
Chondrocyte respiration after cartilage injury 
 Mitochondrial respiratory function in MFC cartilage was assessed by measuring oxygen 
consumption rate (OCR) in the acute phase (from 2-6 hours) after injury. Representative curves 
for OCR are shown in Figure 4.2a, and demonstrate differences in respiratory function between 
low impacted, high impacted and control cartilage. MT respiration declines with increasing 
injury magnitude, revealing acute impact-induced MT dysfunction (Figure 4.2); There was a 
significant effect of treatment (impact) group on bOCR (F4,56 = 5.4135, p = 0.0009) and mOCR 
(F4,56 = 3.0572, p 0.026). Cartilage injury resulted in a 20-32% decrease in bOCR in explants 
from impact groups M2 - M4 (Figure 4.2b), and a 26-44% decrease in mOCR in groups M3 and 
M4 compared to un-impacted controls (Figure 4.2c). Parameters of respiratory control  
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Figure 4.2.  Respirometry reveals acute impact-induced mitochondrial (MT) dysfunction. Cartilage 
from the medial femoral condyle was impacted at various magnitudes (M1-M4) and MT respiration was 
quantified by measuring oxygen consumption rate (OCR), then normalizing data to live cell number for 
each explant. A) Representative curves for OCR versus time for control, low impact (M2) and high 
impact (M4) groups demonstrate differences in MT respiratory function between groups. Note that 
oligomycin-inhibited respiration does not reach steady state (121 minutes), but Rot+AA inhibited 
respiration does (225 minutes.) B) Baseline OCR (bOCR) and C) maximum respiration (mOCR) 
decreased with increasing impact magnitude (M1-M4). Groups that do not share a letter are significantly 
different at p <0.05. Error bars = ±s.d. 
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calculated using oligomycin-inhibited OCR (oOCR) could not be reliably determined because 
steady state OCR following oligomycin treatment was not reached in the majority of samples 
(Figure 4.2a). Injury had no effect on ECAR (p = 0.66).  
 Chondrocyte death in MFC cartilage was positively correlated with impact magnitude 
(Figure S4.1), with the strongest correlation associated with peak impact stress (r2 = 0.70, 
p<0.0001). A significant increase in cell death was observed above 7MPa peak stress, 
establishing a threshold for acute chondrocyte death in this model system. Cell membrane 
damage was assessed in cartilage-conditioned media obtained from wells following the 
respirometry assay, and revealed 2-3 fold increase in LDH activity for explants impacted at 
higher peak stresses (M3, M4) compared to lower impacts (M1, M2) and controls (Figure 
S4.2a). Based on the time-course experiment, LDH activity peaked at approximately 5 hours 
following cartilage injury at all impact magnitudes (Figure S4.2b).  
 
Comparison of Chondrocyte Response to Injury in MFC versus PFG cartilage 
 Similar to MFC explants, chondrocyte death in PFG explants was positively correlated 
with peak impact stress (r2 = 0.79, p<0.001; Figure S4.1).  However, chondrocytes from PFG 
cartilage, a non-weight-bearing articular surface, were more sensitive than the MFC to impact-
induced cell death; PFG explants experienced an approximately 2-fold and 5-fold increase in cell 
death over controls at the lower (M1) and higher (M2) impact magnitudes, respectively (Figure 
4.3).  At lower impact magnitudes (M1), MFC viability was not affected. 
 Cartilage from the PFG was more sensitive to impact-induced MT respiratory 
dysfunction (Figure 4.4). The basal oxygen consumption rate of viable PFG chondrocytes was 
significantly lower in groups impacted at the lowest (M1) and higher (M2) magnitudes compared 
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to un-injured control cartilage, whereas in MFC cartilage, bOCR was only affected at the higher 
impact magnitude (M2). Relative MT membrane potential (MT polarity) was used to assess the 
functional integrity of the inner MT membrane by calculating the R:G ratio, which represents the 
ratio of polarized to depolarized MT within each explant. In uninjured controls, MT polarity was 
similar in MFC and PFG cartilage. MT polarity was significantly decreased in both the lower 
(M1) and higher (M2) impacted explants from the PFG. Over this range of impact magnitudes, 
no statistically significant differences were detected between control and impacted samples from 
the MFC (Figure 4.5). 
 
Discussion 
 
 The goal of this work was to investigate the role of mitochondria in the very early 
response of cartilage to mechanical injury. The most important findings of this study were that 
MT dysfunction is an acute response of chondrocytes to cartilage trauma, and that the response 
of chondrocytes to injury differs based on location within a single joint.  
 Although several lines of investigation have supported the assumption that MT 
participate in catabolic events immediately following cartilage injury,21,29,30 and microscale 
respirometry has recently been used to assess MT function in cultured chondrocytes,17,25 this is  
the first report of assessing in situ chondrocyte MT respiratory function in the acute time frame 
following cartilage trauma. This distinction is important for several reasons. First, chondrocyte 
phenotype and gene expression change significantly when cells are isolated from the native 
extracellular matrix and cultured in monolayer.31-33 In one study, MT metabolism and MT  
biogenesis were drastically altered in both primary cultured (i.e. non-passaged) and first-passage  
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Figure 4.3. Impact-induced chondrocyte death differs by location within the joint.   
A-C) Representative images of PFG cartilage stained for live cells (green) with calcein AM and dead cells 
(red) with ethidium homodimer and imaged in cross-section using confocal microscopy. A) Un-impacted 
control cartilage had less dead (red) staining than B) lower impacted (M1) and C) higher impacted (M2) 
PFG explants. D) Chondrocytes from the patellofemoral groove (PFG) were more sensitive to impact-
induced cell death than the medial femoral condyle (MFC). At lower impact magnitudes (M1) MFC 
viability was not affected. Groups that do not share a letter are significantly different at p <0.05. Error 
bars = ±s.d.   
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Figure 4.4.  The patellofemoral groove (PFG) is more sensitive to impact-induced MT respiratory 
dysfunction than the medial femoral condyle (MFC).  The basal oxygen consumption rate (bOCR) of 
viable chondrocytes was significantly lower in PFG cartilage (red box and whisker plots) impacted at the 
lowest (M1) and higher (M2) magnitudes compared to un-injured control cartilage, whereas in MFC 
cartilage (blue box and whisker plots), bOCR is only affected at the higher impact magnitude (M2). 
Groups that do not share a letter are significantly different at p<0.05. Error bars = ±s.d. 
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Figure 4.5.  The patellofemoral groove (PFG) is more sensitive to impact-induced MT 
depolarization than the medial femoral condyle (MFC).  A) Representative confocal images of control 
and impacted (M2) PFG explants stained for MT polarity at low (top) and high (bottom) magnification. 
Cartilage is stained with Mitotracker Green (green; all MT), tetramethylrhodamine methyl ester 
perchlorate (red; polarized/functional MT), and Hoechst 33342 (blue; nuclear counterstain, higher affinity 
for cells with compromised cell membranes). Red:green fluorescent intensity ratios were calculated on an 
image-wide basis using multiple low magnification z -stacks for each explant (top) using a custom ImageJ 
macro. This technique was validated on a single-cell basis by manually drawing ROIs around single cells 
at higher magnification (bottom). B) MT depolarization occurred in PFG cartilage from both the lower 
(M1) and higher impact (M2) groups compared to PFG controls. Significant differences were not detected 
between impact groups from the MFC. Asterisks denote a significant difference compared to control at p 
<0.05.  Error bars = ±s.d.  
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chondrocytes.34 Secondly, accurate modeling of mechanical trauma to cartilage requires the 
native ECM. Finally, our primary objective was to investigate MT function within hours of 
mechanical injury, and the time required to isolate and perform primary chondrocyte culture is 
incompatible with this goal.  
 Recent evidence suggests that the main determinant for the development of PTOA is the 
magnitude of the initial cartilage/subchondral bone injury.1 A challenge in the field of early 
PTOA research has been to establish thresholds for mechanical injury in vitro and correlate these 
to the development of disease. Recently, our group fully characterized the mechanics of an in 
vivo impactor system and correlated impact magnitude (stress and stress rate) with structural 
damage in vitro.23 A threshold for superficial ECM cracking was established above a peak stress 
of 13 MPa. In the present study, the same impact system was used to determine the relationship 
between impact magnitude and tissue damage (i.e., chondrocyte death and cell membrane 
damage) in the acute phase after cartilage impact. That study revealed cell death was correlated 
to impact stress above a threshold of 7 MPa in MFC cartilage. In the current study, MT 
respiration in viable cells declined with increasing injury magnitude. This suggests a population 
of unhealthy but viable chondrocytes undergoing impact-induced MT dysfunction. This sub-
population of dysfunctional cells may represent a target for therapeutics that would protect MT 
function, prevent cell death, and block perpetuation of tissue damage. To more specifically 
investigate this hypothesis, present studies are focused on improving spatial and temporal 
resolution of MT dysfunction in whole cartilage in the peracute (minutes to hours) time frame 
after injury and following the fate of depolarized cells for days to weeks after impact. 
 Our finding that MT dysfunction occurs independent of cell death is in agreement with 
recent work by Coleman et al,17 which demonstrated MT dysfunction and oxidative stress after 
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one week in chronically overloaded cartilage. The loading regimen consisted of load-controlled 
cyclic compression at 0.25 MPa (physiologic loading) or 1 MPa (supra-physiologic) amplitude 
and 0.5 Hz frequency for 3 hours once daily for one week. Slow load rise times resulted in stress 
rates in the MPa/sec range. In that study, no differences were observed in chondrocyte viability 
or mechanical behavior of the tissue between the physiologically loaded and overloaded 
chondrocytes after 7 days. Furthermore, no differences in MT function or oxidation status were 
observed between groups after one day. Therefore, their model may aptly be described as 
chronic, moderate overloading.  
 In contrast, the current study was designed to more closely model acute cartilage trauma, 
and utilized an energy-controlled spring-loaded device to deliver a single rapid impact, with 
impact times in the millisecond range and stress rates in the GPa/sec range. In addition to distinct 
mechanobiology in these 2 systems, Coleman et al. models the early chronic time frame, with 
MT function assessed 1-2 weeks after start of loading, whereas the aim of this study was to 
assess the acute responses of chondrocytes after injury. This is an important distinction, because 
the subcellular mechanisms occurring within these time frames are likely different. Chronic MT 
dysfunction, as occurs in aging, can encompass many cellular processes including chronic 
oxidative stress, altered mitochondrial dynamics (MT biogenesis, turnover, and plasticity), 
metabolic reprogramming, and inflammation through a complex network of signaling pathways, 
while acute mitochondrial dysfunction occurs following traumatic injury before transcriptional 
changes can occur.35,36 Examples of disease processes mediated by acute MT dysfunction 
include ischemia reperfusion injury after acute myocardial infarction (MI), neuronal damage 
following traumatic brain injury (TBI), and here we propose PTOA.37 Clinical MI and TBI 
research focuses on potentially treatable events in the early phase following injury. In this acute 
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phase, MT participate in both the perpetuation of tissue damage, as well as protective 
mechanisms. For example, following injury, rapid calcium buffering occurs, whereby Ca++ flows 
into the cytosol due to changes in cell membrane permeability and is rapidly sequestered within 
MT. This process leads to MT swelling within 10 minutes of TBI.  MT swelling is reversible if 
cell repair mechanisms remain intact and the MT transition pore (MTP) does not open.38 
Opening of the MTP results in further osmotic swelling of the MT, complete uncoupling of 
oxidative phosphorylation, rupture of the MT membrane and subsequent cell death. Calcium 
signaling is known to be involved in chondrocyte death after injury,21 and our data supports 
impaired efficiency of the ETC after cartilage injury, consistent with acute swelling of the MT.     
  Our findings suggest that chondrocytes of the MFC are less sensitive to impact-induced 
cell death and MT dysfunction than those of the PFG. The MFC and PFG sites were selected 
because the cartilage in these locations is subjected to distinct physiological loading regimens.  
As the major weight-bearing surface of the knee, the MFC is exposed to the highest compressive 
and shear strains, and is a common site for focal cartilage lesions within the knee.39 In contrast, 
the inferior aspect of the PFG is a non-weight bearing articular surface and is often used as a 
donor harvest site for cartilage autograft procedures.40 The inferior PFG articulates with the 
patella alone, and only when the knee is in maximal flexion, so it experiences relatively low 
compressive and shear forces.41 It therefore stands to reason that chondrocytes in these regions 
are adapted to respond differently to injurious loading. Recently, post-impact chondrocyte 
viability was found to differ between joints,42 but to our knowledge, this is the first report of 
regional differences in impact-induced cellular responses within the same joint. Differing 
thresholds for MT dysfunction and cell death could be the result of distinct chondrocyte 
populations and/or site-specific structural variations in the ECM of these regions. Regardless, our 
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findings suggest that there are differences in tissue-scale mechanotransduction between weight 
bearing and non-weight bearing regions within a joint. This is particularly interesting related to 
MT function, as MT act as mechanotransducers in other tissues, converting stress and strain 
experienced by the tissue to chemical signals in the form of ROS.7,18,43 Clinically, this finding 
may have important implications for osteochondral grafting procedures, because a more 
thorough understanding of the mechanisms underlying local differences in mechanotransduction 
may inform selection of optimal autograft and allograft harvest sites.  
 When interpreting the results of this study, it should be noted that all experiments were 
performed at 21% O2 concentration, which is considered relative hyperoxia for cartilage.44 There 
is considerable disagreement in the literature regarding the effect of O2 concentration on 
chondrocyte metabolism.45-48 Most studies have investigated this question in isolated 
chondrocytes, after days or weeks in culture. One group assessed the OCR of freshly harvested 
cartilage (1mm cubes) from young mature (18-24 month old) bovids and found that at O2 
concentrations between 5 and 21%, OCR was relatively constant at ~10 nM/106 cells/hour,47 a 
value comparable to the bOCR values measured for un-injured cartilage in the present study. 
Furthermore, OCR in cultured chondrocytes was found to be independent of O2 and glucose 
concentration in short term (48 hour) culture.46 Therefore, the caveat of relative hyperoxia is 
unlikely to have bearing on our finding of acute impact-induced MT dysfunction.  
 A limitation of the current work is the use of immature cartilage. Previous work has 
shown that young bovine cartilage is more metabolically active and more sensitive to injury-
induced apoptosis than mature cartilage.49,50 Although the magnitudes differ between young and 
mature tissue, chondrocytes respond to injurious mechanical loading with increased cell death, 
intracellular ROS, increased catabolism and a decrease in anabolic activity, regardless of donor 
 114 
age. The rationale for selecting young cartilage for this proof of concept study is that 
chondrocyte density in young cartilage is approximately twofold higher in the first 1mm of depth 
from the articular surface than adult cartilage, maximizing our ability to measure impact-induced 
changes in OCR in situ, over a broad range of impact magnitudes.51 Further studies are 
warranted investigate the effect of tissue maturity on the acute response of chondrocytes to 
injury, as well as the specific mechanisms of acute impact-induced chondrocyte MT dysfunction.  
 In summary, this study demonstrates that MT dysfunction is an acute response of 
chondrocytes to cartilage impact and is the first report of adapting microrespirometry to study the 
subcellular mechanisms of impact-induced chondrocyte MT dysfunction in situ. Our results 
reveal impact-induced decline in basal OCR and maximum respiratory capacity, which suggests 
inhibition of the MT electron transport chain (ETC). This finding is consistent with the known 
phenomenon of MT membrane swelling after injury, which causes unfolding of the cristae 
leading to decreased efficiency of the ETC.9 Cartilage from the weight-bearing surface of the 
distal femur (MFC) is more resistant to impact-induced MT dysfunction and cell death than that 
of a non-weight bearing surface (PFG).  This suggests regional differences between weight 
bearing and non-weight bearing articular surfaces, either due to structural differences of the 
ECM or cellular response to injury and/or differences in mechanotransduction. Our findings 
suggest that direct targeting of MT respiratory function in the acute stages after cartilage injury 
may represent a viable therapeutic strategy in the prevention of PTOA.   
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Supplement 4.1 - Detailed methods !
Microscale Respirometry 
 Each well of a specialized XF24 islet capture microplate (Seahorse Biosciences) was pre-
loaded with assay media (bicarbonate-free DMEM supplemented with 2.5mM glucose, 2mM L-
glutamine, 2 mM pyruvate, and 1% FBS.) The XF sensor cartridge is equipped with 4 injection 
ports per well, which allow automated addition of drugs during the experiment. Approximately 
one hour prior to experimentation, three of the four injection ports were preloaded with MT 
inhibitors to perform a MT stress test. Concentrations for MT inhibitors were determined by 
preliminary dose response optimization assays. The sensor cartridge was allowed to equilibrate 
in a 0%-CO2 incubator prior to being loaded into the XF24 analyzer for calibration.  
 Cartilage slices were prepared as follows; immediately following cartilage injury, a 3mm 
biopsy punch was used to harvest 2 cylindrical plugs from each explant. These plugs were then 
trimmed to 500um thickness from the articular surface using a custom jig cartilage using a 
custom cutting jig and tissue slicer blade (Thomas Scientific, Swedesboro, NJ). Cartilage was 
kept hydrated, each cut was performed with a new and lubricated instrument, and handling of the 
tissue was strictly minimized. Cartilage slices (n = 20 per assay; 3mm diameter by 500µm thick) 
were loaded into the islet capture plate, articular surface facing up, then the capture screens were 
snapped in place to retain the cartilage at the bottom of each well. Four wells containing media 
only served as background control wells. The plate was equilibrated in a 0%-CO2 incubator for 
one hour and then loaded into a Seahorse XF24 analyzer for analysis. The time between cartilage 
impact and start of the assay was a mean of 154 minutes (range 143-167).  
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Image analysis  
 Digital image analysis was carried out using ImageJ software (Mac OS X version 10.2, 
Wayen Rasband, U.S. National Institutes of Health, Bethesda, MD, USA; website: 
http://rsb.info.nih.gov/ij/download.html) with macros customized for each imaging channel. Key 
parameters including pixel intensity threshold and max/min particle size were optimized based 
on manual counts of a minimum of 5 z-stacks obtained from both control and impacted explants. 
Following optimization, all images were digitally analyzed using the same macro as follows: 
Each individual image in a stack was thresholded based on mean pixel intensity of that image, 
then individual particles were identified and counted based on particle size. A mean value (e.g. # 
of dead cells) for each stack was calculated by averaging the values for all 10 images in that 
stack and excluding any image outside one standard deviation of the mean. This was done to 
minimize any potential artifact from the cut surface in the superficial slices and/or differential 
changes in signal intensity between channels based on imaging depth in the deep slices, and 
resulted in exclusion of approximately one image per stack (range 0-2). At least two stacks were 
acquired per explant (mean 3, range 2-4), and final reported values are the mean for all stacks 
acquired of that explant.  
 
Normalization of respirometry data 
 Calculation of cell density: For each image, the imaging field was set at 512pixels 
(775um) wide, and the depth of imaged tissue from articular surface to the bottom of the imaging 
field was measured digitally using the ImageJ software measuring tool, with the average depth of 
700(±22.8)µm. The volume of tissue imaged was calculated as the width x average depth x 10µm 
slices.  This resulted in an average calculated chondrocyte density of 0.22x106 cells/mm3, which 
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is in excellent agreement with Jadin, et al., who used more sophisticated technique (3D image 
analysis) to measure cell density in fetal and calf MFC. They estimated density of 0.3 x106 
cells/mm3 at the articular surface and 0.15x106 cells/mm3 at a depth of 0.5mm from the articular 
surface.51  
 Calculation of explant volume: Following completion of the XF assay, explant discs were 
bisected, placed cut-surface down on a glass cover slip and imaged using an inverted light 
microscope. Digital images were obtained and the volume of each explant was calculated using 
ImageJ software by 2 methods; 1) the diameter of each explant was measured using the line 
measuring tool, 6-8 thickness (height) measurements were obtained at 90° to the diameter 
measurement, then the volume of the cylinder was calculated as = π (diameter/2)2  x mean 
thickness, and  2) cross-sectional area of each hemi-cylinder was measured using the tracing tool, 
then the volume of the explant was calculated as = π * radius2 (area of cut surface/diameter). 
Values for individual explant volume were obtained by averaging the tissue volume obtained 
using both methods of calculation.   
 
 
 
 
 
 
 
!
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Supplementary Figures !
 
 
 
 
 
 
 
 
 
 
 
 
Figure!S4.1.!Chondrocyte death is correlated with impact magnitude. Cell death was positively 
correlated with peak impact stress for both the MFC and PFG (PFG r2 = 0.79, p<0.001; MFC r2 = 0.70, 
p<0.0001). Data presented is for all impacts performed throughout this study.  
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Figure S4.2. Cartilage impact results in cell membrane damage. Cell membrane damage was 
quantified in cartilage explants from the medial femoral condyle by performing lactate dehydrogenase 
(LDH) activity assay on cartilage-conditioned media following respirometry assay. A) Cell damage was 
increased in explants impacted at higher magnitudes (M3 and M4) compared to un-impacted controls; 
Asterisks denote significant increase compared to controls at p <0.05. B) LDH activity in cartilage 
conditioned media peaks at approximately 5-7 hours after impact.  Error bars = ±s.d. 
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Abstract 
 
Objective: No disease modifying osteoarthritis (OA) drugs are available to prevent posttraumatic 
osteoarthritis (PTOA), and mounting evidence suggests that intervention must occur shortly after 
injury to slow or halt disease progression. Mitochondrial (MT) dysfunction plays a central role in 
aging and mediates the pathogenesis of many complex, degenerative diseases including 
syndromes that develop secondary to traumatic injury. MT dysfunction is well documented in the 
later stages of OA, and recent evidence indicates that MT dysfunction is a peracute (within 
minutes to hours) response of cartilage to mechanical injury. A novel class of MT-targeted 
peptide antioxidants has been found to have preclinical efficacy in treating several diseases by 
targeting and stabilizing the MT-specific phospholipid, cardiolipin. The effect of these peptides 
on cartilage have not previously been investigated. The goal of this study was to investigate 
targeted mitoprotection as a strategy to prevent chondrocyte death and cartilage degeneration 
after injury. 
Methods: Cartilage was harvested from the knee joints of 6 neonatal bovids. Cartilage explants 
were subjected to single, rapid impact (24.0 ±1.4 MPa peak stress; 53.8 ±5.3 GPa/s peak stress 
rate) using a subcritical damage model. Explants (n = 7/group) were treated with SS-31 (1uM) 
immediately after injury (T0), one hour following injury (T1), or 6 hours after injury (T6), and 
then cultured for 7 days. Cartilage conditioned media was sampled at 0, 1, and 6 hours, then 
every 24 hours after injury for up to 7 days. Explants were stained with calcein AM and ethidium 
homodimer to quantify live and dead chondrocytes, respectively at 1 and 7 days after injury 
using confocal microscopy. Live, dead, and total cell numbers were quantified in z-stacked 
digital images using a custom ImageJ macro. To quantify cell membrane damage, cartilage 
conditioned media was analyzed using a colorimetric lactate dehydrogenase (LDH) activity 
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assay, and cumulative cell membrane damage over the 7-day incubation period was determined 
for each explant. Cartilage matrix degradation was quantified by measuring GAG loss into the 
media via DMMB assay.  
Results: SS-31 treatment at 0, 1, or 6 hours after impact significantly reduced chondrocyte death 
at 24 hours (P < 0.001), resulting in chondrocyte viability similar to that of un-injured controls. 
This effect was sustained for up to a week in culture, with chondrocyte viability in all groups 
similar on day 1 and 7 after injury. SS-31 prevented impact-induced apoptosis at 1 day (p = 
0.007) and 7 days (p = 0.04) after cartilage injury. Cumulative cell membrane damage over the 7 
days following injury was 2-fold lower in treated than untreated cartilage. Impact-induced GAG 
loss was decreased by ~30% in explants treated with SS-31 (p = 0.002).  
Conclusions: This study is the first investigation of targeted mitoprotective therapy in cartilage. 
Our data demonstrate that SS-31 prevents chondrocyte death, cell membrane damage, and 
cartilage matrix degradation after cartilage injury. These results suggest that even when 
treatment is delayed by up to 6 hours after injury, mitoprotection may be a useful strategy in the 
prevention of PTOA.   
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Introduction 
 
 Bioenergetic failure, cumulative oxidative stress, and MT-mediated apoptosis are 
implicated in the pathogenesis of a wide variety of degenerative diseases, including 
neurodegenerative diseases, metabolic disorders and syndromes initiated by trauma.1-3 A 
significant body of evidence suggests that MT dysfunction occurs in the later stages of 
osteoarthritis (OA), and MT-associated disease pathways are linked to chronic OA changes 
including decreased synthesis of extracellular matrix proteins, pathologic calcification of 
cartilage and upregulation of catabolic cytokines including MMP 1, 3, and 13.4-13 One notable 
study demonstrating MT respiratory dysfunction in chondrocytes isolated from OA patients, with 
lower spare respiratory capacity and higher proton leak compared to healthy chondrocytes.5 They 
also demonstrated that OA cartilage has higher levels of oxidative damage to lipid membranes, 
and that these changes are associated with depletion of the MT-specific antioxidant superoxide 
dismutase-2 (SOD2).  
 Increasing experimental evidence also suggests that MT dysfunction plays a role in the 
pathogenesis of early OA. Redox imbalance and apoptosis are prominent features of early 
PTOA, and ROS are well established early mediators of the disease.6,9-13 MT-derived ROS have 
also been linked to chondrocyte death after cartilage injury.14,15 In an in vitro model of chronic, 
moderate cartilage overloading, MT respiratory function and ATP production declined and 
oxidative stress occurred after one week.16 Several recent studies have also identified MT 
dysfunction in experimental models of early-chronic post-traumatic POTA. For example, 
chondrocyte respiratory function was found to be reduced 4 weeks after surgical destabilization 
of the medial meniscus (DMM) in rabbits.17 In mice, MT superoxide overproduction and SOD2 
down regulation occurred in knee cartilage 2 weeks after DMM.7 The same group demonstrated 
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accelerated cartilage destruction in aged (12 month) chondrocyte-specific SOD2-knockout mice 
(SOD-2 cKO). Chondrocytes isolated from young SOD-2 cKOs displayed MT depolarization, 
decreased MT respiratory function and swollen MT, with disrupted cristae structure on electron 
microscopy. They went on to show that proteoglycan content was decreased and extracellular 
matrix metabolism was impaired by down regulation of anabolic genes and upregulation of 
catabolic genes, including MMP-13. These findings indicate that MT respiratory dysfunction and 
redox imbalance due to overproduction of ROS by MT and/or deficient MT-antioxidant defenses 
very likely play an important role in the early pathogenesis of OA.    
 Evidence for the central role of MT dysfunction in OA has led to interest in developing 
clinical therapies that target MT-associated pathways. For example, many groups have found 
free radical scavengers such as N-acetyl cysteine and vitamin C, to be protective in animal 
models of PTOA, however antioxidants have not provided benefit in clinical OA patients.4,7,18,19 
This may be due to their inability to penetrate cell membranes and reach the MT, where ROS are 
generated.20,21 Caspase inhibitors, including synthetic inhibitors of caspase 3 and 9, prevent MT-
mediated cell death by preventing activation of the caspase cascade and apoptosis in vitro, but 
have not been tested clinically.18,22 These promising drugs act on MT-associated pathways of cell 
death and cartilage degradation but target downstream consequences of MT dysfunction. Ideally, 
to prevent the initiation and progression of PTOA, interventions would be target the very earliest 
disease pathomechanisms.23 Therefore, the concept of targeting MT directly is attractive, 
however no mitoprotective therapies have been investigated as potential disease modifying OA 
drugs.  
 A novel class of MT-targeted peptide antioxidant drugs, Szeto-Schiller (SS) peptides are 
currently being  developed as mitoprotective therapeutics.21 SS peptides are water soluble, cell-
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permeable, and concentrate over 1000 fold in the inner MT membrane. One member of this 
class, SS-31 prevents MT dysfunction, improve MT bioenergetics, reduce MT ROS generation, 
inhibits MT depolarization and prevents caspase-3 activation in addition to directly scavenging 
ROS.1,21 SS-31 exerts all of these effects through its specific interaction with the MT-specific 
phospholipid, cardiolipin (CL).24,25 
 Cardiolipin is exclusively expressed on the inner MT membrane, and comprises ~10% of 
its content.26 The conical structure of CL promotes curvature of the inner MT membrane and 
formation of cristae structure. Curvature of the inner MT membrane and CL rafts allow electron 
transport chain proteins to form supercomplexes, and anchors the non-integral/soluble 
cytochrome C to the inner MT membrane. By arranging and maintaining the electron transport 
chain proteins in close proximity, CL improves the efficiency of electron transfer, optimizing 
ATP production and reducing ROS generation. CL also modulates the opposing actions of 
cytochrome C, which can either execute the rate-limiting step of oxidative phosphorylation, or 
dissociate from the inner MT membrane and trigger apoptosis.27 During MT stress, peroxidation 
of CL results in loss of cristae structure, a decline in ATP production and dissociation of 
cytochrome C form the inner MT membrane, setting the stage for apoptosis. SS-31 selectively 
binds and protects cardiolipin from oxidation, thereby preserving MT cristae structure, 
promoting electron transfer and inhibiting ROS production.25  
 SS-31 is currently in stage II clinical trials for the treatment of several MT-mediated 
diseases including acute coronary syndrome, renal failure, MT myopathy and diabetic 
retinopathy.25,28 SS-31 has not previously been studied in cartilage. The goals of this study were 
to test mitoprotection as a strategy to prevent PTOA, and investigate the therapeutic window for 
treatment after injury. Specifically, we tested if SS-31 can prevent impact-induced chondrocyte 
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death and cartilage degeneration, and if mitoprotective efficacy is affected by the time of 
administration after impact. 
 
Methods 
 
Tissue harvest 
 Full thickness cartilage explants were harvested from the knee joints (n = 12 joints) of 
healthy bovids (n = 6 animals, 1-3 days of age) within 48 hours of sacrifice using an 8mm biopsy 
punch. Specimens were rinsed in phosphate-buffered saline (PBS), trimmed to a uniform 
thickness of 3mm from the articular surface using a custom jig, and placed in cartilage explant 
media (phenol free DMEM containing 1% FBS, HEPES 0.025ml/ml, penicillin 100U/mL, 
streptomycin 100U/mL and .1g/L glucose). Experiments were approved by Cornell University’s 
Institutional Animal Care and Use Committee. 
 
Rapid impact injury model  
 Explants were subjected to injury using validated rapid-impact model, or served as un-
impacted controls, as previously described.29 Briefly, explants were positioned in a well 
containing PBS under the plane-ended tip of a spring-loaded impacting device.30,31 The impactor 
was used to deliver a single, rapid cycle of unconfined axial compression (24.0 ±1.4 MPa peak 
stress; 53.8 ±5.3 GPa/s peak stress rate). Impact force was measured at 50 kHz by a load cell 
(PCBPiezotronics, Depew, NY) attached to the impactor tip. Voltage from the load cell was 
recorded with a custom LabVIEW program (NI, Austin TX). The impact magnitude was 
adjusted by setting the deflection of the impactor’s internal spring and mechanical parameters for 
each impact were calculated as previously described.29  
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SS-31 treatment  
 Following injury, explants were cut perpendicular to the articular surface into 2 
hemicylinders using a custom cutting jig to ensure uniform geometry. Cartilage was kept moist 
at all times and each cut was performed with a fresh (unused) and lubricated cutting instrument. 
Handling of the experimental tissues was strictly minimized at each step. Explants were placed 
directly into an individual well of a 24-well untreated tissue culture plate containing a known 
volume (1.5ml) of cartilage explant media. Cartilage hemicylinders were randomly assigned to 
one of 8 treatment groups (n = 7/group, Figure 5.1). Injured (I) and uninjured control (C) 
explants in the non-treated groups (ITX, CTX) were placed into wells containing only media. 
Explants in the time zero treatment groups (IT0, CT0) were placed directly into media containing 
SS-31 (1µM). Explants in the one-hour treatment groups (IT1, CT1), were placed into media, and 
SS-31 (1µM) was added to the wells 1 hour after impact. In the final groups (IT6, CT6), SS-31 
was added 6 hours after impact (Figure 5.1). Explants were maintained under standard tissue 
culture conditions (36°C and 21% O2) for 7 days. Medium was sampled at 1, 6, and 24 hours, 
and at 3, 5, and 7 days after impact, and stored at -80°C until biochemical assays were 
performed. Culture media was replaced with fresh media (no SS-31) after 24 hours, then every 
other day for the duration of the experiment. After imaging was complete on day 7, cartilage 
explants were lyophilized and weighed for normalization of LDH and DMMB data.  
 
Chondrocyte viability  
 At 1 or 7 days, cartilage was rinsed three times, then placed in PBS containing calcein 
AM (2uM) and ethidium homodimer (1uM) for 30 minutes at 37°C in the dark, to stain live and  
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Figure 5.1.  Study design. Half the cartilage explants were impacted (X) at time 0. Injured groups (I; red 
bars) and non-injured groups (C; grey bars) were then treated (O) with SS-31 (1µM) at time zero (T0), 1 
hour after injury (T1), 6 hours after injury (T6), or left untreated (TX). Explants were imaged on day 1 or 7 
for cell death or apoptosis, and cartilage conditioned medium was collected at 1 hour, 6 hours and 1, 3, 5 
and 7 days after injury to assess cartilage matrix degeneration (GAG loss) and cell membrane damage.  
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dead cells, respectively. Explants were then rinsed in PBS and imaged on a Leika SP5 confocal 
microscope. Digital z-stacked images were acquired in two channel sequential scans (green; 
488/498-544 and red; 514/563-663 nm excitation/emission, respectively) using a modified 3D 
scanning protocol consisting of 10 z-stacked 512x512 pixel (387.5µm x387.5µm) images spaced 
10um apart in the z plane at 10x magnification.  
 The number of live, dead, and total cells in each image was quantified using a custom 
ImageJ (Mac OS X version 10.2, Wayen Rasband, U.S. National Institutes of Health, Bethesda, 
MD) macro. Pixel intensity threshold, max/min particle size, and particle circularity were 
optimized for each imaging channel based on manual counts of a minimum of 5 z-stacks 
obtained from control and impacted explants. Following optimization, all images were digitally 
analyzed using the same macro as follows: red and green channels for each image were 
thresholded based on mean pixel intensity of that image, then individual particles were identified 
and counted based on particle size and circularity. For each image, the % of dead cells was 
calculated as the number of dead cells counted in the red channel divided by the total number of 
cells (live + dead) counted in both channels. To minimize artifact from cell death occurring at the 
cut surface, the average % dead cell for all images in a z-stack was calculated, and any individual 
image with a value outside one standard deviation from the mean was excluded from analysis. 
This resulted in few images being excluded (mean 1 image per stack, range 0-2). The final 
reported values for live, dead and total cells were calculated as the mean of a minimum of 3 z-
stacks obtained for each explant.   
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Apoptosis (activated caspase staining) 
 At 1 or 7 days cartilage was rinsed with PBS three times, then placed in PBS containing 
CellEvent Caspase 3/7 (Molecular Probes, Eugene, OR) to stain for activated caspase activity. 
Explants were imaged in on a Leika SP5 confocal microscope. Digital z-stacked images were 
acquired in two channel sequential scans (488/498-544 excitation/emission, respectively to 
image apoptotic cells and reflectance to highlight collagen in the extracellular matrix) using a 
modified 3D scanning protocol consisting of 10 z-stacked 512x512 pixel (387.5µm x387.5µm) 
images spaced 10um apart in the z plane at 10x magnification. The number of caspase-positive 
cells per field were counted using a custom ImageJ macro, as described above and expressed as 
the number of apoptotic cells per mm2.    
 
Cell membrane damage  
  Imaging studies were validated with biochemical assays performed on cartilage-
conditioned media. As a measure of cell membrane damage, the release of lactate dehydrogenase 
(LDH) from cartilage explants into culture media was quantified using an LDH activity assay 
(Sigma-Aldrich) that detects NADH, which is reduced from NAD by LDH. The assay was 
executed per the manufacturer’s instructions. Briefly, equal volumes of cartilage conditioned 
media and kit reagent were added to a 96-well assay plate (Corning, Corning, NY) and 
absorbance was measured at 450nm in 5-minute intervals by a spectrophotometric microplate 
reader (Tecan Safire; Männedorf, Switzerland). Using a standard curve generated by dilutions of 
NADH, LDH activity was calculated following subtraction of background media values and 
expressed as milliunits of LDH per ml of cartilage conditioned media. 
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Cartilage GAG loss  
 To determine if SS-31 could provide structural protection after impact injury, the loss of 
glycosaminoglycan (GAG) was determined by routine 1,9-dimethyl-methylene blue dye binding 
(DMMB) assay, as previously described.32 Briefly, media samples were digested using papain 
(Sigma Aldrich, St. Louis, MO) 0.25 mg/ml at 65°C for 4 hours. A standard curve was prepared 
using chondroitin-4-sulfate (Sigma Aldrich). Equal volumes of sample and DMMB dye (Sigma 
Aldrich) were mixed in a 96-well plate. Total GAG content was read fluorometrically, and 
expressed as the total GAG released into cartilage conditioned media over the culture period per 
µg dry weight of cartilage. 
 
Statistical analysis 
 Data were analyzed using a linear mixed effects model, with a random effect of trial and 
fixed effects of injury (I, C), treatment time (TX, T0, T1, T6), and response time, including all 
interactions. Comparisons between groups were performed using Tukey’s HSD method. 
Residual analyses were performed to ensure the assumptions of normality and homogeneous 
variance were met. Differences were considered statistically significant when p ≤ 0.05. All 
statistical analyses were performed using JMP Pro Version 11.0 (SAS Inc.) software. 
 
Results 
 
Chondrocyte death and apoptosis 
 Cartilage impact resulted in a roughly 3-fold increase in the amount of cell death at 1 day 
post-injury (Figure 5.2a). At 1 day, SS-31 potently reduced cell death in all injured treatment  
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Figure 5.2.  SS-31 prevents impact-induced chondrocyte death at day 1 and day 7.  
A) Chondrocyte death (% dead cells) in injured explants treated with SS-31 at 0, 1, or 6 hours was 
equivalent to uninjured controls. Timing of treatment did not affect chondrocyte viability. B) SS-31 was 
effective at preventing chondrocyte death on day 1 and 7 post-impact. C) Representative confocal images 
of uninjured (control), injured (impact) and injured, treated (impact + SS-31) cartilage on day 1 and 7. 
Explants are stained for live and dead cells with calcein AM (green) and ethidium homodimer (red), 
respectively. Groups that do not share a letter are significantly different at p ≤ 0.05. Error bars = ±s.d. 
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groups (IT0; p = 0.0007, IT1; p < 0.0001, IT6; p = 0.0003); this equates to over 50% reduction in 
impact-induced chondrocyte death in treated versus untreated explants (ITX). In all injury + 
treatment groups, chondrocyte viability was similar to un-injured controls (CTX; p = 0.16). Cell  
death also did not differ between injury groups treated at 0, 1, or 6 hours, indicating no effect of 
treatment time (p = 0.93). When chondrocyte viability was assessed on day 7, the same trends 
were present; SS-31 prevented impact-induced cell death to a similar degree, regardless of 
whether treatment was applied immediately following, at 1 hour or at 6 hours after impact 
(Figure 5.2). Note that since no effect of treatment time was detected on day 1 or day 7, groups 
T0, T1 and T6 were collapsed and represented as a single treatment group in Figures 5.2b – 5.4. 
Cell death was not significantly different on day 1 and day 7 in uninjured, non-treated (CTX) 
explants (p = 0.98), indicating baseline chondrocyte viability was maintained for the 7-day 
culture period (Figure 5.2). 
 Activated caspase 3/7 staining of injured explants on day 1 and 7 revealed an increase in 
the number of apoptotic cells throughout the depth of the cartilage (Figure 5.3). SS-31 prevented 
impact-induced apoptosis at 1 day (p = 0.007) and 7 days (p = 0.04) after cartilage injury. There 
was a trend toward fewer apoptotic cells on day 7 than day 1 in all groups, most notably in 
injured, treated explants but this difference did not reach statistical significance (p = 0.07).  
 
Cell membrane damage and cartilage GAG loss  
 Cumulative cell membrane damage, quantified by LDH activity in cartilage conditioned 
media over the 7 days following injury, was approximately twofold lower after injury in treated 
than untreated cartilage (p = 0.0005, Figure 5.4). SS-31 also appears to have a protective effect 
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Figure 5.3. SS-31 prevents impact-induced apoptosis. A) Apoptosis in injured explants treated with 
SS-31 was equivalent to uninjured controls at day 1 and 7. B) Representative confocal images of 
uninjured (control), injured (impact) and injured, treated (impact + SS-31) cartilage on day 1 and 7.  
Explants are stained for activated caspase 3 and 7 (caspase+) and imaged using reflectance to highlight 
collagen in the extracellular matrix (matrix.) Groups that do not share a letter are significantly different at 
p ≤ 0.05. Error bars = ±s.d. 
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Figure 5.4.  SS-31 prevents impact-induced chondrocyte membrane damage and cartilage matrix 
degradation.  A) LDH activity in the media of injured, treated groups is lower than injured, untreated 
explants, and similar to uninjured controls. SS-31 also appears to have a protective effect against cell 
membrane damage in treated controls (p = 0.05). B) Cumulative GAG loss into the media on days 3-7 
was increased in injured, untreated explants compared to uninjured controls. GAG loss was similar in 
injured, treated and control groups. Groups that do not share a letter are significantly different at p ≤ 0.05. 
Error bars = ±s.d.       
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against cell membrane damage in uninjured controls; uninjured, treated samples had a lower 
cumulative LDH than untreated controls (p = 0.05). Impact-induced GAG loss was decreased by 
~30% in explants treated with SS-31 (p = 0.002, Figure 5.4).  
 
Discussion 
 
 The purpose of this study was to investigate the effects of mitoprotection on chondrocyte 
death and matrix degradation after cartilage injury. To investigate the possible clinical relevance 
of SS-31 as a “point-of-injury” therapy to prevent cartilage degeneration if administered in the 
acute stages following cartilage trauma, a time course experiment was performed. This study 
demonstrates that SS-31 prevents injury-induced chondrocyte death, apoptosis, cell membrane 
damage, and matrix degradation. Even when treatment was delayed by up to 6 hours after injury, 
mitoprotective therapy may be a useful strategy in the prevention of PTOA.  
 Somewhat surprisingly, no detectable effect of treatment time was observed in this study. 
Previous in vitro work indicates that cell death staining peaks at 2-3 hours following impact,33  
MT respiratory dysfunction occurs within 2 hours of impact (Chapter 4) and MT depolarization 
occurs within minutes of impact (un-published data, in progress). Further evidence suggests that 
following injury, a subset of chondrocytes experience MT-dysfunction but remain viable for an 
indeterminate amount of time. We therefore hypothesized that SS-31 would act to stabilize this 
subpopulation of cells and prevent MT-mediated cell death in the earliest treatment groups (T0, 
T1) more effectively than the T6 group. There are several possible explanations for why no effect 
of treatment time was detected. First, the outcome measure of cell death (i.e. % dead cells 
quantified by live/dead cell staining at 1 and 7 days post-impact) measures non-specific cell 
death and may not be sensitive enough to detect small differences in treatment time groups. 
! 142 
Although calceinAM/ethidium homodimer (EtHD) staining is a commonly used to quantify 
chondrocyte viability, EtHD is actually an indicator of plasma membrane integrity because it 
gains access to the cytosol through permeabilized cell membranes, and fluoresces when bound to 
nucleic acids.34 Therefore, EtHD–positive staining may identify cells at any point along a 
continuum between potentially rescuable cell membrane damage and death. Activated caspase 
3/7 staining is a more specific measure of cells committed to apoptotic cell death, and detection 
of caspase activation should exclude the population of cells that presumably rupture immediately 
upon impact, cells with damaged cell membranes that remain viable, and cells undergoing 
necrotic cell death. In the current study, the outcome measure of apoptosis by treatment time 
sample size was low (n = 4), and individual group data were not presented. Ongoing experiments 
to increase statistical power, and methods to normalize the number of caspase-positive cells by 
total cell number rather than cartilage volume, may reveal significant differences in apoptosis 
between T0, T1 and T6 groups. One would expect that further delaying treatment (e.g. 12 hours 
after impact) would reveal an effect of treatment time, and further studies are underway to 
identify this temporal threshold.   
 Although unexpected, our finding of equivalent mitoprotective efficacy with treatment 
delayed up to 6 hours is supported by other studies. MT-mediated cell death evolves over a 
slower time scale than necrotic cell death (days versus hours, respectively).13,33,35-38 The pathway 
of MT-mediated cell death by apoptosis is initiated when cytochrome C (CytC) dissociates from 
the inner MT membrane and Bcl-2 proteins cause permeabilization of the outer MT membrane, 
allowing Cyt C to other MT proteins to leak into the cytosol. CytC initiates oligomerization of 
APAF-1, recruitment and dimerization of caspase-9 and formation of the apoptosome. Activated 
caspase-9 cleaves caspase-3 and -7 and these activated ‘executioner’ caspases commit the cell to 
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death by apoptosis. Evidence suggest these events, from MT permeabilization to caspase 3/7 
activation are rapid, occurring over ~10 minutes.39 However, the events leading up to MT 
permeabilization may be more gradual. In injured cartilage, delayed MT depolarization has been 
linked to cumulative oxidative stress as well as accumulation of specific ROS, namely 
NO.13,35,40,41 Time course studies of progressive apoptosis in cartilage have been investigated by 
several methods, and suggest that chondrocyte apoptosis may be initiated around 6 hours and 
sustained for up to 7 days post-injury.35,36,38 Therefore, it is reasonable that mitoprotection 
initiated at 6 hours may be sufficient to rescue cells undergoing impact induced MT-dysfunction 
but not yet committed to programmed cell death. Ideally, to further define the therapeutic 
window for mitoprotective therapy after cartilage injury, additional time-points would be 
investigated.  
  GAG release into cartilage-conditioned media is a well established indicator of cartilage 
injury.38,42 In the present study we found that GAG loss was significantly increased in injury 
groups versus controls starting on day 3 post-injury. This is different than the findings of 
Patwari, et al. and others who found that GAG loss was increased in injury groups compared to 
controls between days 1 and 3 post-injury, but not after day 3.42 The reason for this difference is 
unclear, however, is likely related to the different loading regimens employed. Patwari used a 
displacement controlled mechanical testing frame to deliver unconfined compression to 50% 
strain, while our spring-loaded impactor delivered an energy-controlled cycle of compression. 
The most significant difference is the rate of loading; although peak stresses in both studies were 
very similar (23 MPa versus 24 MPa), load in the current study was delivered over 1-2 
milliseconds (~54GPa/s peak stress rate) versus 0.1-0.2 seconds by Patwari. This is important 
because immediate and non-sustained GAG loss, as seen in other models, suggests that the cause 
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is mechanical disruption of matrix rather than to cell-mediated enzymatic degradation.42 This is 
supported by the finding that incubation of cartilage with protein synthesis inhibitors did not 
effect GAG release after injury. A lag time in injury-induced GAG release in the present study, 
and inhibition of GAG release by SS-31 suggests that mitoprotection prevents injury-induced 
cartilage matrix degradation.   
 This was designed as a proof-of-concept study to support the strategy of mitoprotection 
after cartilage injury. We therefore focused on the time-dependence of SS-31 treatment, but did 
not investigate dose-response. The dose 1µM was chosen based on preliminary experiments, 
however a full dose-response study would be useful to optimize the protective effects of this 
drug. Ex vivo studies of SS-31 peptides in other tissues suggest this drug may be effective at 
nanomolar concentrations. It is clinically important to note that SS-31 has no effect on normal 
cells and no cytotoxic or mitotoxic effects have been observed in studies at concentrations 
exceeding 100uM ex vivo, up to 10mg/kg in vivo animal models, and up to 0.25 mg kg−1 h−1 over 
4 hours in human safety studies.21  
 A concern with any cartilage-targeted osteoarthritic drug is question of diffusion through 
the avascular, highly charged cartilage matrix. Owing to their unique chemical structure, SS 
peptides are extremely water soluble, while able to freely diffuse (translocate) across lipid 
membranes by a phenomenon known as transcellular transport.43 This results in a volume of 
distribution similar to blood volume, and no accumulation in lipid, further limiting concerns for 
toxicity.  
 In summary, this study demonstrates that mitoprotection with SS-31 prevents 
chondrocyte death and cartilage matrix degradation, even when treatment is delayed up to 6 
hours after cartilage injury. The unique properties of this class of drugs confer their ability to 
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provide structural protection to MT cristae by specifically interacting with cardiolipin, thereby 
preventing MT dysfunction.25 Our data suggest that SS-31 has the potential to be the first 
effective disease modifying osteoarthritis drug.  
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CHAPTER 6 
 
GENERAL DISCUSSION 
 
Thesis summary and significance 
 The goal of this thesis was to investigate mitochondrial dysfunction as a potential 
therapeutic target to prevent PTOA. Although a large body of evidence supports MT dysfunction 
in the early-chronic and late stages of OA, this work is the first to directly assess MT respiratory 
function in situ within hours of impact injury, and link these findings with indicators of cartilage 
degeneration.1,2 We confirmed that MT respiratory dysfunction is an acute response of 
chondrocytes to injury. This forms the basis of our rationale to investigate mitoprotection as a 
point-of-care therapy to prevent PTOA after joint injury. This strategy is used in other diseases 
of MT dysfunction mediated by acute mechanical trauma and ischemia-reperfusion injury, for 
example traumatic brain injury and myocardial infarction, respectively. The concept is to limit 
ongoing tissue damage following the initial insult. Although not directly assessed in this body of 
work, SS-31 also holds promise in the treatment of established disease, and our findings have 
potential implications in age-related/idiopathic OA.3-5  
 
Future directions  
Basic science/mechanistic questions 
 Mechanisms of MT-related mechanotransduction in chondrocytes. Based on our work 
and others, it is clear that MT participate in the acute transduction of mechanical forces into 
cellular signaling within chondrocytes, but the exact mechanisms remain unclear.6-9 A more 
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nuanced understanding of these acute-phase pathways may have important implications for the 
development of drug therapies as well as orthopedic regenerative medicine and tissue 
engineering applications.    
 The extent to which, and the conditions under which acute MT mechanotransduction 
participates in, or is mediated by soluble and/or physical/structural elements is an evolving area 
of investigation. Both soluble factors such as Ca2+, ROS, and fibronectin fragments, as well as 
physical/structural elements are known to play important roles mechanotransduction pathways 
connecting cartilage injury to the down-stream catabolic signaling cascades responsible for 
irreversible cartilage degeneration.10-14 For example, studies have implicated Ca2+ signaling as a 
primary mechanism underlying MT dysfunction in articular chondrocytes15 and the role of ROS 
has been discussed throughout this thesis. Integrin signaling is involved in both soluble and 
structural mechanotransduction. Fragments of ECM proteins, most prominently fibronectin 
fragments, can bind to integrin receptors and initiate intracellular MAP kinase pathways 
mediated catabolic signaling.14 In addition to integrins, many transmembrane cell surface 
receptors are known to transduce physical and chemical stimuli to the chondrocyte including 
cytokine receptors, toll-like receptors and others. For example, binding of ECM type II collagen 
to the receptor tyrosine kinase discoidin domain receptor (DDR) 2 activates the 
RAS/RAF/MEK/extracellular-regulated kinase (ERK) signaling independent of integrin and 
cytokine signaling, and leads to upregulation of MMP-13, the major type II collagen-degrading 
collagenase considered a marker for OA progression.14  
 Other physical/structural components of chondrocyte mechanotransduction include 
structural components of the ECM, namely type II collagen, the pericellular matrix (PCM), made 
up of collagen VI, fibromodulin, and matrilin, and the chondrocyte actin/myosin/intermediate 
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filament cytoskeleton.16-19 The PCM plays an important role at the interface between mechanical 
signals and gene expression in response to compression20 and the mechanical properties of the 
PCM can play a protective role by modulating local chondrocyte strain during compression.21 
Mechanical forces influence chondrocyte cytoskeletal organization and cytoskeletal components 
are known to play a central role in the transduction of mechanical stimuli to biochemical 
responses.22,23 For example, mechanical loading causes differential deformations of organelles24 
and actin microfilaments and microtubules act to transfer strain to intracellular organelles, 
including the MT.25 Direct links between these ECM-PCM-chondrocyte cytoskeletal proteins to 
the MT have not been well investigated in cartilage, but some evidence exists in other tissues. 
MT are tethered to the cytoskeleton yet are highly mobile, and evidence suggests MT use 
cytoskeletal proteins as tracks to move along during intracellular transport.26 At the same time, 
cytoskeletal proteins influence MT dynamics (fission/fusion), shape and function in other tissues, 
and recent evidence suggests crosstalk between receptors that control MT organization, 
movement and apoptosis.26 The mechanisms by which local mechanical forces and physical 
deformations of the ECM, PCM and the cytoskeleton influence chondrocyte MT function and the 
initiation of PTOA are questions that our group is just beginning to explore. For example, recent 
work by Bonnevie, et al. (Bonnevie ED, 2016 Doctoral thesis) suggests that chondrocyte MT 
depolarization is correlated with local shear strain during cartilage sliding. Furthermore, this 
work connects MT depolarization and chondrocyte apoptosis with increased frictional 
coefficients due to inadequate cartilage lubrication.        
 Finally, interesting research implicates the primary cilium in chondrocyte 
mechanosensing,27-30 however very little information is available regarding interaction between 
this organelle and the MT network. In light of the current work that supports a role for MT as 
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acute mechanotransducers in chondrocytes, the possible physical and biochemical relationships 
between these organelles are intriguing and warrant investigation. 
 Detailed tracking of cell fate - timing and mechanisms of impact-induced chondrocyte 
death. Our research suggests that immediately after cartilage injury, there are at least three 
distinct population of chondrocytes: 1) dead cells, 2) cells that are alive and functioning 
normally, and 3) viable cells with MT dysfunction. What is unknown is the fate of cells in group 
3.  Presumably, they can either go on to die by non-specific, necrotic, or apoptotic cell death, 
recover and re-enter group 2, or continue to survive and remain dysfunctional, thereby 
contributing to ongoing tissue damage. Our ongoing studies include a more detailed investigation 
of the spatial and temporal distribution of MT dysfunction and cell fate after mechanical injury 
will provide useful insights into the mechanisms of impact-induced chondrocyte death and the 
critical window for mitoprotective therapy after joint injury.   
 Mechanism of chondroprotection by SS-peptides. Our findings indicate that targeted 
mitoprotective therapy prevents cell death and cartilage degeneration, however the mechanism 
has not been investigated in this work. Because chondrocyte metabolism is significantly different 
from more energy-expensive tissues such as skeletal muscle, improved bioenergetics may not be 
the primary means of chondroprotection by SS-31 observed in our work. Instead, the beneficial 
effects of SS-31 may be due to its role in reduced ROS generation and free radical scavenging. 
Several methods could be used to investigate this theory. Repeating the studies performed in 
chapter 5 with SS-20 would provide useful mechanistic insight, because SS-20 acts by a very 
similar mechanism as SS-31, but lacks the ability to scavenge free radicals. Transmission 
electron microscopy studies are in progress to evaluate the efficacy of SS-31 to protect 
chondrocyte MT christae structure after injury. Microrespirometry studies similar to those 
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performed in Chapter 4 could provide information about the effect of SS peptides on 
chondrocyte bioenergetic function after injury. Finally, the development of a reliable and 
practical assay for the immediate detection of ROS/redox imbalance/oxidative damage to lipid 
membranes in whole cartilage would be very useful, but to date, efforts have been 
unrewarding.31,32 
 
Preclinical and clinical testing of mitoprotection to prevent and treat osteoarthritis 
 Preclinical testing of SS-31 in animal models of PTOA. Surgical destabilization (e.g., 
DMM) and non-invasive destabilization models of knee of PTOA in mice are well validated, 
relatively inexpensive, and have been used as screening tools to test many putative PTOA 
therapies.  Limitations of these models were discussed in Chapter 2, nevertheless, a mouse study 
is a practical first-step to investigate the efficacy of SS-31 to prevent PTOA. Our group has work 
in progress to develop a method of non-invasive anterior cruciate ligament rupture in the mouse, 
which will be used to evaluate the efficacy of SS-31 in prevention of PTOA secondary to joint 
destabilization.  
 For the reasons outlined in Chapter 2, the next logical step, in conjunction with small 
animal model studies, is to test the preclinical efficacy of SS-31 in our equine model of impact-
induced talocrural PTOA.  Plans to further develop and validate this model include: 1) In vivo 
confocal/multiphoton cartilage imaging. Our group, in collaboration with the Cornell Imaging 
Core, has been working to develop an arthroscopically adapted microscope. This technology 
would allow us to study cellular events immediately following cartilage injury, and connect them 
directly with disease development in vivo. Much of the preliminary work has already been 
completed. Horses will undergo arthroscopic surgery, as described in Chapter 3. Following 
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cartilage injury, the impactor will be swapped with an aiming device, to accept an 
arthroscopically adapted multiphoton microscope. Sodium fluorescein will be added to the 
arthroscopic fluid to stain dead cells, and TMRM will be used to image MT function in vivo. 
Cartilage will be imaged for cell death, matrix cracks and MT depolarization in vivo for up to 4 
hours. Horses will be treated with SS-31 intraarticularly, and development of PTOA will be 
assessed as described in Chapter 3; 2) Additional synovial fluid biomarkers of early OA that 
have been validated in equine PTOA models will be assessed on ELISA;33,34 3) Evaluation of 
OA- and MT-related gene expression profiles in cartilage and synovium; 4) Clinical 
(antemortem) and research (postmortem) grade MRI. Collaborators at the musculoskeletal MRI 
unit at Hospital for Special Surgery/Weill Cornell Medical College, will perform 3T MRI 
evaluation of the joint after euthanasia, and cartilage will be studied using quantitative T2 MRI 
mapping, as previously reported.35,36 Fast spin echo sequences will be used to image the articular 
cartilage and surrounding soft tissues. Short tau inversion recovery and spectral fat suppression 
will be used to detect subchondral bone pathology. Quantitative pulse sequences will be used to 
assess collagen orientation and proteoglycan content.  
 Clinical testing of mitoprotection to prevent PTOA in veterinary patients. Veterinary 
orthopedic patients represent a high-risk population for development of naturally occurring 
PTOA. The two species that are athletic and prone to PTOA are horses and dogs. In dogs, the 
most common cause of lameness and the most common surgically treated orthopedic injury is 
rupture of the cranial cruciate ligament (CCL).37 Most dogs diagnosed with CCL rupture display 
radiographic signs of OA, which often progresses despite surgical intervention.38-40 It is therefore 
feasible to design a prospective, randomized clinical trial to test the efficacy of SS-31 to prevent 
radiographic progression of PTOA in dogs presenting for the surgical treatment of acute CCL 
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ruptures. Treatment could commence immediately upon diagnosis, or at the time of surgery. This 
would require collaboration with small animal orthopedic surgeons who perform high volumes 
of this procedure.  
 Similarly in equine patients, several candidate patient populations at risk for developing 
PTOA exist, including racehorses presenting for surgical repair of condylar fractures, and 
arthroscopic removal of osteochondral fragments of the metacarpo/metatarsophalangeal and 
carpal joints. Pharmacokinetic studies would be required in individual species.    
 Clinical trial of SS-31 in human patients. Ultimately, the goal is to test mitoprotection in 
human patients at risk for PTOA after joint trauma. Specific patient populations would need to 
be identified in order to test the point-of-care strategy. This would require large numbers of 
individuals at risk for a specific subset of joint injury, with a point of access to immediate 
medical care. One such population is members of the armed services. In deployed military 
personnel, ankle sprains are the most common non-combat injury with over 15% incidence in 
~4000 soldiers evaluated by a doctor.41 In military cadets, a total of 614 new ankle sprains 
occurred during 10,511 person-years at risk, resulting in an overall IR of 58.4 per 1000 person-
years.42 Each year, 17,000 trainees attend the U.S. Army Airborne School at Fort Benning, GA 
and make ~200,000 parachuting jumps. In this population, ankle injures occur at a rate of 3-6 per 
1000 parachute jumps. These statistics indicate that members of the armed services are at least 5 
times higher risk for ankle injury than the general population.43-45 Other at-risk populations are 
athletes involved in high school, college and professional level sports including basketball, 
soccer, football and rugby.46,47 An alternative to the point-of-injury strategy would be to recruit 
patients being evaluated by orthopedic surgeons for specific acute orthopedic injuries with a high 
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risk of developing PTOA. This might include severe ankle sprains, intraarticular fractures or 
anterior cruciate ligament or meniscal tears of the knee.    
 
Conclusion 
 Largely thanks to advances in biomedical research, expected lifespan has roughly 
doubled over the past 175 years, however expected years with mobility-related disability also 
continues to increase.48 In addition to the enormous financial burden imposed by direct costs 
associated with treating osteoarthritis, the indirect costs of OA are nearly impossible to fully 
quantify.49,50 Going forward, an urgent goal for the biomedical community is to improve healthy 
(disability-free) lifespan. With OA being the leading cause of chronic disability, developing an 
FDA approved disease-modifying OA therapy is an immediate priority. To realize this ultimate 
goal, future work will continue to require a multi-disciplinary approach with biologists, 
engineers, pharmacologists, veterinarians and human clinicians working together to better 
understand the role of MT in OA, and pursue MT-targeted therapies. 
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